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Abstract
The discovery of peptide-based targeted imaging agents is hindered by the required
addition of a radionuclide that can affect the binding properties of the peptide. Screening
of peptide libraries is problematic because they do not take into account the presence of
the imaging agent. Herein the development of an organometallic OBOC peptide library
that contain a rhenium(I) tricarbonyl-based imaging entity surrogate incorporated directly
onto the peptide chain, is reported. Additionally, MALDI tandem mass spectrometry is
reported as a method to deconvolute organometallic peptides containing four different
rhenium(I) tricarbonyl chelates on the N-terminus of octapeptides.

Furthermore, an

organometallic OBOC peptide library is created and screened against the GLP-1R
(glucagon-like peptide 1 receptor) in order to discover potential imaging agents for
diagnosis of diabetes and insulinomas. The methods reported herein can be applied to
develop peptide-based imaging agents for a wide variety of relevant targets.
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Chapter 1: Introduction
1.1 Molecular Imaging

Molecular imaging allows for the non-invasive visualization of molecular
pathways within the body. It can be defined as the visualization, characterization and
quantification of biological processes at the cellular and sub-cellular level.1 The use of
molecular imaging has increasingly played a role in modern medicine because of the
recognition of the importance of being able to detect, differentiate between, and treat
diseases quickly and early in their development without using invasive procedures. As a
result, the development of molecular imaging techniques is an area of intensive research.
There are a number of different molecular imaging modalities that find wide use
in modern medicine such as MRI (magnetic resonance imaging), PET (positron emission
tomography) and SPECT (single photon emission computed tomography). The images
from these modalities are often combined with each other, or techniques such as CT scans
(x-ray computed tomography) to provide information about the presence, development,
progress and potential treatment for a disease.
PET and SPECT are both important molecular imaging techniques in nuclear
medicine. The general definition of nuclear medicine is the injection of radioactive
substances (radiopharmaceuticals) into a biological system for diagnostic or therapeutic
purposes. More specifically, PET and SPECT rely on the introduction of radionuclides
into the body and the subsequent detection of the radiation emitted. If it can be shown
that the radiopharmaceutical preferentially moves to a specific part of the body or type of
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tissue, these techniques can provide a wealth of information about development and
disease.
While PET and SPECT imaging techniques both rely on radionuclides, there are a
number of differences in the way in which radiation is detected. PET relies on the ability
of certain radionuclides, such as carbon-11, flourine-18 and gallium-68, to undergo beta
decay resulting in the emission of a positron. After a positron is emitted, it will move a
very short distance until it comes into contact with an electron, which will result in an
annihilation event. This produces two gamma-rays at an angle of 180o from one another.2
These gamma rays are then detected by two cameras, and the information obtained is
used to create an image.
SPECT imaging detects gamma ray radiation emitted directly from radionuclides.
This can occur by a number of mechanisms such as electron capture whereby a proton in
the nucleus combines with an electron to form a neutron and a gamma ray. This is the
process which allows the use of iodine-123 and indium-111 for imaging purposes.
However, radionuclides such as technetium-99m undergo gamma emission whereby a
nucleus in a high energy state relaxes over time via the emission of a gamma ray.3 The
electromagnetic radiation is then detected by a gamma camera and an image is formed.
Because of the difference in radionuclides necessary for PET and SPECT, the use
of either to diagnose or treat a specific disease is dependent on the discovery of suitable
radiopharmaceutical probes, as well as the presence of necessary imaging equipment and
the availability of specific radionuclides.

3

1.2 PET and SPECT Molecular Imaging Agents

Despite the power of these two nuclear imaging techniques, the expanding use of
SPECT and PET relies on the discovery and development of new radiopharmaceutical
probes. There are two broad classes of imaging agents: targeted and non-targeted. Nontargeted imaging agents rely on general chemical properties such as size, charge and
lipophilicity that determine the movement of the probe within the body.3 Many examples
of these types of imaging agents are currently available and widespread in the clinic, such
as the PET agent

18

F-FDG (fluorodeoxyglucose), a glucose analogue which provides

imaging based on sugar metabolism.4 An example of a SPECT non-targeted imaging
probe for use in heart imaging that has found widespread use is

99m

Tc-MIBI

(methoxyisobutyl isocyanide).5 The lipophilic cation proportionally distributes within the
heart and allows for the effective imaging of blood flow.

Figure 1.1 a) 18F-fluorodeoxyglucose, a widely used analogue of glucose used often to
image tumors due to either high uptake of sugars. b) Tc-MIBI, a non-specific imaging
agent used especially for cardiac imaging.

Conversely, a targeted imaging probe usually contains two distinct parts (Figure
1.2). The first part is the imaging moiety, which for the purposes of SPECT and PET
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must contain a radioactive isotope capable of emitting detectable radiation. The imaging
moiety is responsible for providing radiation in order to facilitate the visualization of the
imaging agent’s location. The second part is a targeting moiety which is responsible for
the imaging agent’s distribution in a biological system, such as binding to a particular
receptor or enzyme.

Figure 1.2 The general formulation of a targeted imaging agent, including a targeting
entity, responsible for interactions with specific receptors, an imaging entity necessary for
visualization and a linker sometimes included minimize interference between the two
entities.

The number of useful imaging nuclei is a small fraction of the known radioactive
elements due to a number of constraints necessary for medical use.

Imaging

radionuclides must have a short enough half-life to emit enough detectable radiation
within a reasonable time frame, as it would be inefficient and result in an unsafe radiation
dose.

Further, the radionuclide must have a long enough half-life in order to be

synthesized, incorporated into a probe and injected into an individual without significant
decay. For example, the most common medical radionuclide, technetium-99m emits
detectable gamma rays with a half-life of approximately six hours. Another example of a
useful medical radionuclide is the positron emitting fluorine-18, which has a half life of
approximately 110 minutes.

The different chemistry of radionuclides also plays an
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important role in the development of imaging entities. Radionuclides such as carbon-11
and fluorine-18 can be incorporated directly into the structure of an imaging agent.
Conversely, when utilizing metallic radionuclides such as technetium-99m and gallium68, a chelate must be formed in order for the metal to be incorporated into the
radiopharmaceutical.
Table 1.1 Common positron emitting radionuclides for PET, showing their half-life and
method of production.6
Isotope
11

Carbon
Nitrogen
15
Oxygen
18
Fluorine
64
Copper
68
Gallium
82
Rubidium
13

Half-life (min)
20.3
9.97
2.03
109.8
768
67.7
1.26

Method of Synthesis
cyclotron
cyclotron
cyclotron
cyclotron
cyclotron
generator
generator

Table 1.2 Common gamma ray emitting radionuclides for SPECT, showing their halflife and method of production.7
Isotope
Gallium
99m
Technetium
111
Indium
123
Iodine
201
Thallium
67

Half-life (hours)
78.3
6
67.9
13.2
73.1

Method of Synthesis
cyclotron
generator
cyclotron
cyclotron
generator

The second necessary part of an imaging probe is the targeting moiety. The
responsibility of the targeting moiety is to move the imaging moiety to a desired part of
the biological system. For example, a targeting moiety might be designed to move
specifically to a particular type of cancer cell, such that when radiation is detected, it will
reveal the location and size of tumors present throughout the body. There are also a
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number of necessary preconditions for a targeting entity to be useful in nuclear medicine.
The targeting entity must have the ability to preferentially go to a desired part of the
body. The targeting entity must also be able to move quickly through the body to the
area of interest, because of the time constraints imposed by using radionuclides.
Additionally, the targeting moiety should not produce an immune response within the
patient as well as being able to be cleared from the body after the imaging has been
completed in order to minimize exposure to ionization radiation.
Because of the necessary preconditions imposed upon a useful targeting entity,
the development of molecular imaging agents relies heavily on the discovery and
development of new targeting entities.

1.3 Peptides as Targeting Entities

Targeting entities can be composed from a diverse array of compounds such as
small molecules, antibodies and peptides. Small molecules, as a class of compounds, can
be very useful targeting entities. They are usually low molecular weight, which in theory
gives them access to a very large number of targets in the body, both intracellular and
extracellular receptors and enzymes. In general, small molecules move quickly through
the body and can be designed such that they have little trouble crossing biological
barriers.

Further, there is a high level of diversity associated with small molecule

targeting entities which allows a wide array of modifications in order improve
performance. In addition, small molecules are not readily degraded by enzymes in the
body. Small molecules are also generally feasible for rapid and efficient addition of
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small radionuclides such as fluorine-18 and carbon-11.8 However, there are a number of
drawbacks when investigating small molecules as targeting entities.

The discovery

process for small molecule targeting agents is difficult and leads to few useable imaging
agents.9

Additionally, because small molecules have low molecular weight, an

acceptable imaging component rarely contains a metal radionuclide due to the overall
mass and size of the chelate; this limits their use as targeted imaging agents.
Another type of targeting moiety are antibodies; y-shaped proteins which are
naturally produced by the body and utilized by the immune system. They are very large
(usually over 100 kDa) and bind to targets with extremely high affinity and specificity.
They are also very stable to degradation in the body and relatively simple to synthesize
biologically. There are a number of FDA approved antibody-based imaging agents;10
however as a class of compounds they suffer from a number of problems. Because they
are often recognized by the immune system of the target, a large number of undesired
side effects are common, even in FDA approved radiopharmaceuticals.11

Further,

because of their large size, they have difficulty reaching targets across biological barriers,
thereby limiting their use. Also, antibodies are not easily cleared from the body, possibly
staying in the blood for weeks, resulting in poor image quality due to noise, and patients
being exposed to high levels of unnecessary radiation.12
Peptides are an important class of targeting entities because of a number of
beneficial properties.

Peptides are larger than small molecules but still small in size

when compared to antibodies. Peptides can possess high selectivity for specific targets as
well as access to a large number of relevant receptors, enzymes and proteins based on
their ability to cross biological barriers.13 Peptides are also thought to be more useful
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than small molecules in targeting enzymes or receptors which exhibit protein-protein
interactions. This because some protein-protein interactions occur over a wide surface
area with no obvious binding pockets.14 These properties make peptides more promising
imaging agents for these particular targets due to their ability to interact in a similar
fashion. Peptides are also a very diverse class of compounds, with the potential to use a
large number of natural and unnatural amino acids, alter the chain length, utilize both L
and D-amino acids and are easily modified. When compared to antibodies, although
peptides generally have lower affinity to targets, peptides rarely produce side effects15
and have more favourable pharmacokinetic properties16,
images.
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resulting in higher quality

Also, peptides are more stable to the harsh chemical modification and

radiolabelling conditions such as elevated temperatures or organic solvents.18

The

beneficial properties of peptide-based imaging agents can be shown by the widespread
use of Octreotide, an

111

In-peptide imaging agent acting on the somatostatin receptor

(Figure 1.3).19 Because of these advantages, peptides as targeting entities have become
important in the development of novel molecular imaging agents.

Figure 1.3 A peptide-based imaging agent containing a D-Phe and D-Trp, octreotide,
acting on the somatostatin receptor. The peptide is cyclised via a disulfide bond and
contains the imaging entity 111In-DTPA (diethylenetriaminepentacetic acid).

9

1.4 Discovery and Development of Peptide-based Imaging Agents

The development of suitable peptide-based molecular imaging agents can broadly
be divided into two categories (Figure 1.4). First, a rational design method can be taken.
This approach relies on modifying peptide or peptide-like structures based on known
information about the target. Second, a random library approach may be taken. In this
method, one screens a large number of peptides (potentially millions) and determines
which ligands show the most promise as imaging agents.

There are a number of

advantages and disadvantages associated with both techniques.

Figure 1.4 Flow chart of the available methods for developing imaging agents
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Rational design has been a successful method in developing peptide-based
therapeutic drugs. There are a number of different tools available in the design of
peptides, such as the truncation and modification of known biological peptides.
Endogenous peptides are rarely useful imaging agents due to their short half-life in the
body. Rational modification of endogenous peptides can result in an increase in desired
properties as well as maintenance of high selectivity and binding affinity. Amino acids
can be altered, D-amino acids can be added to increase biological half-lives, unnatural
amino acids can be added and lipophilicity can be changed with careful modifications.
This provides a wide array of potential tools available in the rational design process.
Structural information can also be taken from the target of interest. If the desired
binding site is known, it is possible to construct a peptide based on the properties of the
target itself.

Computational approaches to peptide-protein interaction using QSARs

(quantitative structure-activity relationships) are useful, however the computational
complexity of determining conformations of relatively large and flexible molecules with
known protein structures has, despite steady advances in predictive ability, serious
limitations.20 High resolution crystallographic information derived from target-ligand
structures remains the most useful tool in designing peptide ligands as they can provide a
wealth of information about specific binding interactions and conformations of the
binding site. Therefore, in utilizing a combination of the above approaches it is possible
to design potential molecular imaging agents. As an example of the rational design
process, the endogenous peptide hormone ghrelin(1-28), a 28 amino acid peptide with an
octanoylated side chain, binds to the growth hormone secretagogue receptor 1 (GHSR1),21 and is a promising candidate for prostate cancer imaging. Rational modification of
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this peptide chain has resulted in a significantly truncated amide peptide, ghrelin(15)amide with effective maintenance of binding affinity.22 Additionally, modification of
the octanoylated side chain with the radionuclides technetium-99m and fluorine-1823 has
produced promising imaging agent candidates.
However, there are a number of serious drawbacks in undertaking a rational
design approach.

The entire rational design method relies on the availability of

information about the specific target of interest. If a rational design approach was to be
undertaken to design a bioactive peptide sequence against a specific target, information
about the endogenous ligand(s) and the binding site must already be known. In many
cases, there is not enough data on the desired target. For example, obtaining crystal
structures of protein active sites or protein-ligand interactions is a non-trivial exercise
which results in few usable structures. Further, of the structures available, comparatively
few protein crystal structures are of high value therapeutic or diagnostic targets, as
membrane bound proteins are particularly difficult and time-consuming to crystallize.24
All rational design processes rely on prior knowledge about the system of interest in
order to develop imaging agents, and in many cases this information is not readily
available. Because of this, other methods have been developed to aid in ligand discovery,
in which a large precondition of target and ligand knowledge is not required.
The use of peptide libraries strives to overcome the drawbacks associated with the
rational design process. In these methods, a large number of sequences are tested for
binding affinity against a desired target. The ligands that have shown high affinity to the
target are identified and then can be further developed as imaging agents. The advent of
large scale economical automation has allowed these methods to become widely
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available. There are a number of benefits to this process. First, the precondition of
ligand and target information is dramatically lessened. Second, in comparison to a
rational design process, a large number of peptides which are potential imaging agents
can be discovered and developed simultaneously for one target. Third, the process is
generally less time consuming than rational design, and potential peptides can be tested
faster and more economically. Fourth, because proteins usually contain many potential
binding sites, the random library approach does not distinguish between sites. As such,
although subsequent tests might be necessary to determine where the peptides bind, this
provides a particular advantage during imaging agent discovery because the peptide
sequence is needed to locate the receptor, as opposed to induce or inhibit biological
activity. Furthermore, combinatorial approaches can be used in conjunction with the
rational design process to aid in the discovery of new peptide ligands.
Because of these benefits, a large variety of random libraries have been developed
for the purpose of generating bioactive peptide ligands. Generally, peptide libraries
involve the synthesis of random sequences of amino acids on a solid support of some
kind. Random peptide libraries can further be divided in two categories, spatially and
non-spatially addressable libraries. Because the creation of peptide libraries inherently
results in random peptide sequences, one of the main concerns with random libraries is
determining the identity of a peptide with desired properties.
In spatially addressable libraries, the identity of the peptide is known by its
location on the solid support, such that if an interaction is observed, for example, at a
particular spot on a peptide-coated plate, the location of the spot will allow determination
of the peptide sequence. Two such representative spatially addressable libraries are
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SPOT and light directed libraries. SPOT libraries were first reported by Frank in 199225
and utilize a cellulose solid support on which peptides are built.26 With automation,
activated amino acids can be added sequentially to specific locations such that the
identity of the peptide at that location is known.27 Light directed libraries created by
Fodor et al. rely on a similar set of principles as SPOT libraries, by utilizing photomasks
and photolabile protecting groups.28 Lasers are used to deprotect photolabile protecting
groups at specific locations and activated amino acids are added. When this process is
repeated a number of times, many peptides can be built on the solid support and the
identity of the peptides at each location will be known. One of the main drawbacks
associated with these types of libraries is there is a limit to the number of peptide
sequences which can be screened at any given time. Automation coupled with SPOT or
light directed libraries can only result in tens of thousands of unique peptide sequences.29
Although this is useful for small focused libraries in which only a few amino acids
residues are altered while the others remain constant, large libraries containing perhaps
millions of sequences are often required for drug or imaging agent discovery.
Non-spatially addressable random peptide libraries are defined by the inability to
identify the peptide sequence based on its location. Two such examples of non-spatially
addressable libraries are phage display libraries and OBOC (one-bead, one-compound)
libraries. Both of these libraries require further manipulation of the library in order to
identify the bioactive peptide sequence. However, it is possible to screen significantly
more peptide sequences than in spatially addressable libraries, potentially numbering in
the millions.
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Phage display libraries are a broad classification of a type of biological library.
The general process for creating phage display libraries (Figure 1.5) is as follows:
phages, which are viruses infecting bacterial cells, are engineered with DNA coding for
specific peptide sequences, which are then randomly mutated to create a large number of
variations. After infection of E. coli cells with these phages, the peptide sequences are
synthesized as a coat protein for the phage.30 A phage display library has the potential to
display billions of peptide sequences, of which bioactive peptides are identified based on
DNA sequencing. Moreover, phage display libraries can be used to investigate relatively
large polypeptides in comparison to other synthetic methodologies.

Recently,

Chakravarthy et al. utilized phage display libraries to discover a 174 amino acid
polypeptide acting as an inhibitor to a protein kinase C enzyme,31 a class of proteins that
are important pharmaceutical targets.

Figure 1.5 Overview of the methodology associated with utilizing phage display
libraries for discovering peptide-protein interactions.

The problems associated with phage display libraries are mainly that there is a
limitation to the types of peptides available to be tested.

During the process of
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transcription and translation of DNA into peptides, the biological machinery recognizes
specific DNA sequences which correspond to specific peptide sequences. Because of
this, the biological phage display library can only display peptides created from natural
amino acids. Peptides containing only natural amino acids are prone to quick degradation
within the body and generally need to be modified with unnatural or D-amino acids.
Despite these disadvantages, phage display libraries are popular because of their
unparalleled diversity, commercial availability and speed at which bioactive peptide
sequences can be obtained.
OBOC libraries are another type of non-spatially addressable libraries. Unlike
phage display libraries, OBOC libraries are not biological in nature. OBOC libraries
involve the sequential synthesis of peptides on solid support beads. This technique
utilizes standard solid-phase peptide synthesis to build amino acid chains on beads
composed of an insoluble backbone.

The creation of OBOC peptide libraries employs a

split-mix methodology (Figure 1.6).

Figure 1.6 The synthesis of OBOC peptide libraries, where A-E are amino acids, using
two mix-split steps. The number of possible peptide sequences increases exponentially
with each step, following the formula N = pa, where N is the number of sequences, p is
the number of amino acids in a peptide, and a is the number of amino acids available.
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A group of single beads is split into a number of discrete wells, which correspond
to the number of amino acids used. The amino acids are then coupled to the beads.
Subsequently, the beads from each well are then recombined and mixed together. This
mix-split cycle is then repeated as many times as necessary to produce the desired length
of peptide.32 With every mix-split cycle, the number of possible sequences increases
exponentially.
sequence.

In this way, each bead will contain many copies of unique peptide

When compared to phage display libraries, OBOC peptide libraries are

generally smaller however they potentially still contain millions of sequences.
However, OBOC peptides have the advantage of being able to contain unnatural
amino acids, D-amino acids as well non-peptide structures. For drug or imaging agent
development this is a powerful tool because, as previously mentioned, these
modifications are usually necessary for a peptide to be stable in biological conditions.
OBOC libraries have been used to discover compounds with high binding affinities to
specific receptors; examples include cyclic peptides which bind to breast cancer cell
lines,33 cyclic peptides which bind in high affinity to the somatostatin receptor which is
over-expressed in certain tumours,34 and linear peptides which interact with RGD
proteins.35

These individual beads can then be tested against a specific target to

determine which beads contain a bioactive peptide sequence.
libraries, the bioactive peptide sequences must be identified.

Like phage display
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1.5 Deconvolution and Identification of Peptide Sequences

The two primary methods in order to identify unknown peptide sequences are
Edman degradation and tandem mass spectrometry.

Reported in 1950, Edman

degradation involves the use of phenylisothiocyanate which reacts with a free amine
present at the N-terminus of the peptide to form a cyclical derivative that contains the
original terminal amino acid. This can then be removed from the N-terminus of the
peptide

without

disrupting

any

other

amino

acid

monomers

to

form

a

phenylthiohydantoin amino acid derivative.36

Scheme 1.1 Edman degradation utilizing phenylisothiocyanate to form a
phenylthiohydantoin derivative.

Because the side chains are present in this derivative, original amino acid identity
can be identified by chromatography and mass spectrometry. This method is useful as it
requires a minimal amount of peptide, is capable of unambiguously identifying any
natural amino acid based on their side chain and the ability to sequence peptides directly
from a solid support. However, Edman degradation has a number of limitations. The
process is time-consuming and prohibitively expensive when identifying a large number
of peptides. Further, there is a requirement of an N-terminal amine which is not usually
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desirable in imaging probe development due to a general lack of biological stability
associated with peptides containing free N-terminus.
Tandem mass spectrometry relies on the ionization of the peptide, either through
ESI (electrospray ionization) or MALDI (matrix-assisted laser desorption/ionization)
techniques.37, 38 A peptide ion is identified and subsequently fragmented and the resulting
ions can then be used to identify the peptide sequence. This method is fast, economical
and has few prerequisites in terms of the peptide’s structure. For example, tandem mass
spectrometry can be used to identify peptides with acetylated N-termini as well as nonpeptide like motifs. Tandem mass spectrometry is also effective in the presence of
impurities which are common in library screening.39 However, in most cases prior to
sequencing, peptides need to be cleaved from solid support. Further, the amino acids
leucine/isoleucine and glutamine/lysine are isobaric and therefore indistinguishable via
common mass spectrometry methods.40 In addition, peptide fragmentation is largely
sequence specific; individual peptides might not produce all required fragments for
unambiguous sequence determination.41 Mass spectrometry for peptide identification can
be useful in screening large numbers of peptides for use in nuclear medicine because of
the versatility allowed in the structure of the bioactive molecule.
There is a wide array of combinatorial tools available in order to find bioactive
peptide sequences for use in discovering new targeting entities. These libraries can
provide an alternative or complementary method to the rational design process.
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1.6 Organometallic OBOC Peptide Libraries

Molecular imaging agents are not often developed via the combinatorial approach
due to a number of difficulties associated with the technique. Regardless of the method
employed, testing targeting entities for bioactivity fails to take into account the rest of the
potential imaging agent. The targeting entity is only one portion of an imaging agent. In
addition to the targeting entity, an imaging entity containing a radionuclide, a chelate or
prosthetic group and occasionally a linker to attach the imaging entity to the targeting
entity, is required. This presents the problem where after testing for bioactive peptide
sequences and determining their identity, a subsequent modification is always necessary
to add an imaging moiety. In the case of small peptides (<2000 Da) and small molecules,
the addition of a metal chelate and possibly a linker can account for a significant portion
of the overall mass of the potential imaging agent.42 This can dramatically change the
bioactivity of the targeting entity. 43, 44 A demonstration of this is shown by the reduction
of the binding affinity of the 5-iodobenzovesamicol from an IC50 = 2 nM to an IC50 = 280
nM upon the addition of a technetium-99m chelate as shown in Figure 1.7.45

Figure 1.7 5-iodobenzovesamicol and the compound with a technetium chelate. The
addition of the imaging moiety decreases binding affinity by over 100 fold.
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In general, as targeting entities, either small molecules or peptides, become larger,
the effect of the imaging entity on the binding affinity becomes less drastic. However,
even moderately sized peptides have been shown to be influenced significantly by metal
chelates. An example of the addition of rhenium(V) and technetium(V) complexes to a
somatostatin receptor-binding peptide, containing nine amino acids, with an initial
binding affinity of 1.8 nM results in the decrease in binding affinity by approximately
eleven fold.46 Also, the addition of a large chelation system can affect the lipophilictiy
and electronic properties of the compound, as well as altering the conformations of the
molecule. All of these can potentially have negative effects on the binding affinity such
that the peptide sequence is no longer viable as a molecular imaging agent.
This is an inherently inefficient system because after identifying bioactive peptide
sequences, the next step is to alter the properties of the compound. The addition of an
imaging entity to a targeting entity is especially troublesome during high throughput
library screening because knowledge of how the targeting entity binds to the target as
well as its conformation in three dimensions is not usually known; this results in a
general lack of understanding as to how the addition of an imaging entity might lower the
initial peptide’s binding affinity. Because of the problems associated with the addition of
an imaging moiety, it is apparent that the development of imaging agents poses unique
challenges of which new methods are required in order to facilitate their discovery.
Therefore, in order to counter these problems, the development of an
organometallic OBOC peptide library is proposed. The introduction of a radionuclide
surrogate into the peptide library prior to screening has the potential to overcome the
problems associated with using traditional peptide libraries to discover molecular
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imaging agents. This method has the potential to account for changes in binding affinity
due to radionuclide incorporation; there also exists a possibility to screen for bioactive
peptide sequences which only show activity when a radionuclide is present. This type of
compound would not have been identified using traditional techniques.
Rhenium is used as a non-radioactive surrogate for the technetium-99m
radionuclide. Technetium-99m is the most widely used radionuclide in modern nuclear
medicine accounting for approximately 85% of radiopharmaceutical injections. Because
non-radioactive isotopes of technetium do not exist, rhenium is often used to mimic the
chemical properties of technetium. Rhenium is located directly below technetium in the
periodic table, and due to the lanthanide contraction, has similar size, coordination
properties and bond lengths.47 As such, a rhenium(I) tricarbonyl containing OBOC
peptide library is proposed for identification of potential technetium-99m molecular
imaging agents. A non-radioactive isotope of rhenium is to be attached via a chelation
system to the N-terminus of solid support-bound peptides in an OBOC library. The
decision to utilize one-bead, one-compound libraries is the result of a need to create a
large library for lead compound discovery in order to validate an organometallic library
method. Phage display libraries are biological in nature and limited to natural amino
acids, as such it is not compatible with the addition of organometallics.

When

synthesized, the organometallic OBOC peptide library can be tested against targets useful
in disease diagnosis to develop new potential imaging agents.
The potential also exists to utilize this method on a wide variety of radionuclide
imaging moieties.

Because of the different size and coordination spheres of many

different radionuclides, this method is not limited to the use of rhenium(I) tricarbonyl
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metal cores, but can be expanded to include any radionuclide in any oxidation state. This
method has the potential to be a versatile and universal way to develop molecular
imaging agents. Furthermore, it would be possible to create an organometallic OBOC
peptide library containing multiple different types of chelates or radionuclides, in order to
investigate and account for differences such as size and charge while further increasing
the diversity associated with OBOC peptide libraries.
The creation and utilization of organometallic OBOC peptide libraries would
increase the efficiency in developing new peptide-based SPECT and PET imaging agents.
However, there are a number of preliminary experiments and synthesis that are the first
steps to create a testable organometallic OBOC peptide library.
1.7 Thesis Scope

Rhenium(I) tricarbonyl organometallic chelates are investigated as part of the
development of novel organometallic OBOC peptide libraries. Rhenium is an especially
attractive metal for this purpose.

Firstly, the radioactive isotopes rhenium-186 and

rhenium-188 show much promise in therapeutic nuclear medicine as β- emitters of 1.07
MeV and 2.12 MeV electrons, respectively.48

Secondly, rhenium has very similar

properties to technetium, which is by far the most widely used and available diagnostic
radionuclide in modern medicine. Thus, rhenium is commonly used as a non-radioactive
surrogate to technetium-99m. Thirdly, the rhenium(I) tricarbonyl core is unique in that it
requires comparatively small chelators. The use of large chelators might not be expected
to produce many positive results in conjunction with relatively small targeting peptides
due to the large affects it can exert. Fourthly, rhenium(I) tricarbonyl chelates can easily
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hold a variety of charges depending on the chelation system, further allowing the
investigation into imaging entities’ effects on peptide-target affinity.
With this information, the initial research into organometallic OBOC peptide
libraries involves the synthesis and characterization of rhenium(I) tricarbonyl chelates
holding different charges and with the ability to be covalently bound to a peptide
targeting entity.
MALDI tandem mass spectrometry will be evaluated as a method to identify and
sequence peptides containing rhenium(I) tricarbonyl chelates. Based on the expense,
presence of a chelate on the peptide N-terminus and the time-consuming nature of Edman
degradation, developing a method of tandem mass spectrometry to sequence
organometallic peptides is the most agreeable, efficient and unconstrained way to create a
method for identifying organometallic peptides.
Ultimately, with rhenium-containing peptides and a method in order to identify
unknown organometallic peptides, an OBOC library will be tested against a useful target
in order to validate the method. A target for such an exercise is the GLP-1R (glucagonlike peptide 1 receptor). Finding a series of imaging agents selectively targeting this
receptor would potentially allow for monitoring of type 2 diabetes as well as a way to
diagnose and treat various insulinomas.
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Chapter 2: Synthesis of Rhenium(I) Tricarbonyl Chelates as Imaging
Entity Surrogates
2.1 Introduction

The first step in the creation of organometallic OBOC (one-bead, one-compound)
peptide libraries is the development of the metal chelates that can be incorporated into
peptide sequences. These metal chelates are to act as imaging agent surrogates. The
surrogates will imitate the size, lipophilicity and charge of an imaging entity without
emitting radiation. There are a number of requirements for these metal chelates that are
imposed by their use as potential imaging agents. All chelates for targeted molecular
imaging need to be bifunctional; they need to form complexes with metal radionuclides,
as well as have a functional group that is able to be attached to the targeting entity.
Further, the chelate needs to be inert in order to withstand the conditions of not only
library screening but also be stable to in vivo conditions for extended periods of time.
Despite these restrictions, there are a wide variety of useful imaging-related metal
chelates which have been investigated.
Technetium-99m is the most popular medical isotope in nuclear medicine. It has
a half-life that is convenient for imaging, as well as the gamma ray emission energy is
approximately 140 keV which is ideal for SPECT.49

Further, the technetium-99m

radioisotope is readily available from generators, allowing for widespread use away from
the cyclotron or nuclear reactor facilities used to create radioactive isotopes. Also,
SPECT imaging facilities are much more widespread than the corresponding PET
facilities, despite the superior properties of positron emission tomography. Because of
these reasons, it is desirable to develop

99m

Tc-based imaging agents. Unfortunately,
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technetium is an entirely synthetic element and does not possess non-radioactive isotopes.
Therefore, rhenium is often used as a non-radioactive surrogate for development,
characterization and testing of imaging agents. Rhenium and technetium have very
similar coordination chemistry, bond lengths as well as having very similar size due to
the lanthanide contraction.

The atomic radius of rhenium is 137 pm and the

corresponding radius of technetium is 136 pm.50

2.1.2 Development of Rhenium/Technetium(I) Tricarbonyl Cores

Rhenium tricarbonyl has increasingly become the subject of imaging-related
research. The rhenium tricarbonyl core was first developed in 1994,51 in order to further
investigate the +1 oxidation state of rhenium and technetium. The rhenium(I) tricarbonyl
core incorporates a reduction of size as well as an increased in vivo stability in
comparison to complexes with other oxidation states of rhenium or technetium.
However, discovery of useful

99m

Tc(CO)3+ imaging agents has been hindered by the

development of suitable methods of synthesis in a time frame imposed by imaging.
When

99m

Tc is eluted from a generator at an imaging facility, it exists as pertechnate,

[99mTcO4]-, and needs to be reduced into the +1 oxidation state. The first methods
utilized carbon monoxide gas under pressure and in the presence of a reducing agent such
as NaBH4.52 These methods are not suitable for synthesis in the radiopharmacy as they
are complicated, time-consuming, use pressurized gas and are unfamiliar.

These

problems were overcome with the development of fully aqueous preparation of
99m

Tc(CO)3+ utilizing potassium boranocarbonate, K2BH3CO2, which is a source of

26

carbonyl ligands as well as acting as a reductant.53 This kit formulation allowed for a
facile way to create radiolabelled compounds by simply mixing the pertechnate with a
premade formulation in order to create technetium(I) tricarbonyl. This method does not
require pressurized carbon monoxide and has increased the interest developing clinically
relevant technetium(I) and rhenium(I) tricarbonyl molecular imaging agents.

2.1.3 The Properties of Rhenium(I) Tricarbonyl Complexes

The chemical stability of rhenium(I) tricarbonyl has been extensively
investigated.

Rhenium(I) tricarbonyl is a low spin d6 metal that forms octahedral

complexes and the metal is considered to be a soft Lewis acid. The metal centre is
polarisable and prefers softer Lewis bases. However, the presence of the three carbonyl
ligands, facially coordinated, significantly adds to the versatility of ligands available to
the rhenium(I) oxidation state. Carbonyl ligands donate electron density through σ bonds
to the metal core, thereby increasing the stability of electron deficient species. Further,
the carbonyl ligands also can accept electron density from an electron abundant species
through the process of π back bonding. Carbonyls are strong field ligands because they
increase the magnitude of the Δoct. This is due to the π* anti-bonding orbitals of the
carbonyl ligands with t2g symmetry; the energy of the d6 electrons is lowered and
therefore produces a more stable complex (Figure 2.1).
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Figure 2.1 Partial molecular orbital diagrams for octahedral complexes of rhenium(I).
The first diagram shows the splitting associated with ligands which do not accept or
donate π electrons. The second diagram illustrates the increase in Δoct associated with
having ligands which accept electron density, as is the case with carbonyl ligands. This
occurs because the symmetry of the π* orbitals and three of the d orbitals of the rhenium
are identical.

This creates molecular orbitals whereby the rhenium(I) tricarbonyl core can
accept a wide variety of “harder” ligands then would be expected, and allows for a wide
variety of chelation systems. The rhenium(I) tricarbonyl core has shown remarkable
diversity in the ligands it can accept, forming complexes with amines,54 aromatic amines
(pyridine,55 imidazole,56 pyrazole57), phosphines,58 thiols,59 thioethers,60 alcohols61 and
carboxylates,62 among others.
The non-reactivity of rhenium(I) tricarbonyl complexes in general is also due to
their high kinetic inertness.

The rhenium(I) tricarbonyl chelates are fully saturated

complexes and the metal core is generally protected from attack by other ligands.
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Investigations into the properties of mono-, bi- and tridentate ligands for
rhenium(I) tricarbonyl cores have been extensive.

Stability and in vivo studies have

shown the tridentate chelators are the most useful for use in molecular imaging.63 Most
tridentate chelates have been shown to be stable to the atmosphere for long periods of
time. Further, in vivo biodistribution studies of tridentate rhenium(I) tricarbonyl show
complete clearance from the body 24 hours post-injection. This is a result of minimal
substitution between the rhenium(I) tricarbonyl chelates and biomolecules in the body
due to high thermodynamic stability and kinetic inertness of the coordination compound.
Conversely, bidentate rhenium(I) tricarbonyl chelates show increased retention in the
kidneys and liver post-injection. Despite very similar lipophilicity and size, the bidentate
chelates act very differently. This is most likely due to the exchange of ligands in
bidentate systems with water and proteins. As such, the in vivo kinetic stability of
bidentate complexes is significantly compromised, leading to the exclusive use of
rhenium(I) tricarbonyl tridentate chelators for imaging purposes.

2.2 Results and Discussion

Four rhenium(I) tricarbonyl bifunctional tridentate chelates have been synthesized
for use in an organometallic OBOC peptide library. A selection of chelates, neutral,
positively and negatively charged, were synthesized in order to obtain a complete
assessment of the usefulness of rhenium(I) tricarbonyl chelates in OBOC peptide
libraries, as there exist imaging agents that contain all of these charge states.
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Two rhenium(I) tricarbonyl starting materials, [Et4N]2[ReBr3(CO)3] and
[Re(H2O)3(CO)3]OTf, were initially synthesized from rhenium(I) bromopentacarbonyl
(Scheme 2.1) These complexes contain bromo- or aqua- ligands which are labile and
easily exchanged due to the trans-effect of the carbonyl ligands. The carbonyl ligands are
able to accept electron density from the attack of a ligand opposite the position of the
carbonyl, thereby stabilizing transition states.64 The tribromo- complex is mildly soluble
in organic solvents such as methanol, acetonitrile and DMF which allows for
incorporation of the rhenium(I) tricarbonyl core into hydrophobic chelates. Conversely,
the triaqua core is water-soluble and allows for facile incorporation water soluble
chelators.

Scheme 2.1 The synthesis of rhenium(I) tricarbonyl starting materials. Compound 2.1
contains three labile bromide ligands which can be easily substituted as well as two
tetraethylammonium counterions. Comparatively, 2.2 contains three labile aqua ligands
and exists in an aqueous solution with a triflate counterion.
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2.2.1 2-Picolylamino-N,N-Diacetic Acid (N,N,O) Rhenium(I) Tricarbonyl Chelate

The chelation system initially investigated was 2-picolylamino-N,N-diacetic acid
(PADA).

This is because it forms neutral complexes with rhenium(I) tricarbonyl

compounds as well as provides three different unique electron donating species; an
amine, a carboxylic acid and a pyridyl nitrogen. The Re(CO)3-PADA complex has been
previously shown to be kinetically stable, enduring acid reflux conditions for 24 hours.52
The molecule is bifunctional as it contains functional groups that form a tridentate
chelation system, as well as a free carboxylate that is used to attach the chelation system
to a peptide sequence. Therefore, it is a good system to test the suitability of rhenium
tricarbonyl cores in organometallic OBOC libraries.
Initially, the PADA complex was synthesized via the use of ethyl ester protecting
groups as shown below:

Scheme 2.2 Synthesis of Re(CO)3-PADA. Reagents: a) Ethylbromoacetate, NEt3, DMF,
0oC. b) KOH, EtOH, 0oC. c) [Et4N]2[ReBr3(CO)3], MeOH
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First, using the nucleophilic properties of primary amines, in an SN2 reaction, 2.3
is formed from picolylamine and ethyl bromoacetate. A single ethyl ester group was
saponified to form compound 2.4 utilizing potassium hydroxide in ethanol. The reaction
involves a selective deprotection of one ethyl ester to form a carboxylate. The difficulty
in this reaction is finding the correct conditions to minimize the instances of both ethyl
esters of 2.3 undergoing saponification. The purpose of maintaining an ethyl protecting
group on a single carboxylate is to stop potential coordination of the rhenium tricarbonyl
core with two carboxylates, which would leave an undesired by-product. Although
conditions were obtained where minimal saponification of both ethyl esters was
observed, a significant portion of starting material was recovered. Subsequently, the
coordination of rhenium through the use of [Et4N]2[Re(CO)3Br3] resulted in the isolation
of 2.5 by silica gel chromatography. The subsequent saponification of the remaining
ethyl ester in compound 2.5 was unsuccessful due to decomposition of the coordination
compound. It was decided that because of the difficulty of the selective saponification of
one ethyl ester as well as the problems with deprotecting the ethyl ester from the rhenium
coordinated species, a new synthetic method would be applied involving less synthetic
steps.
In the second synthetic pathway, the number of synthetic steps required is reduced
significantly. The synthesis of 2.6 involves the amine nucleophile of iminodiacetic acid,
and picolyl chloride hydrochloride. With the addition of potassium hydroxide, 2.6 was
synthesized in approximately 40 % yield after recrystallization from hot ethanol.
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Scheme 2.3 Synthesis of PADA (2.6). Reagents: a) 1. KOH, MeOH, reflux 24 h. 2.
HCl(aq)

Rhenium is then coordinated to form the desired bifunctional PADA-rhenium
chelate. The synthesis of 2.7 by this method significantly reduces the number of steps
required to make large quantities of the desired chelation system. The pyridyl nitrogen is
expected to coordinate preferentially to the rhenium(I) tricarbonyl core, resulting in the
desired tridentate chelate. Although rhenium coordination to both carboxylate groups
was observed, the desired neutral coordination compound was easily isolated.

In

methanol, the neutral coordination compound has low solubility and therefore precipitates
out of solution, whereas the charged coordination compound does not. The product was
then purified by recrystallization from hot methanol resulting in a 58% yield.

Scheme 2.4 Synthesis of Re(CO)3-PADA (2.7). Reagents: a) MeOH, 2.1
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The product was characterized by 1H NMR, 13C NMR and HRMS. The 1H NMR
shows a clear downfield shift of the aromatic proton next to the pyridyl nitrogen due to
the coordination of the Re(I) metal centre. Also, the most obvious coordination induced
change in the 1H NMR spectrum is the shift downfield and the splitting associated with
all of the methylene protons. Compound 2.6 shows two singlets corresponding to the two
chemically inequivalent methylene proton classes. However, due to the creation of a
chiral centre at the nitrogen amine upon the coordination of the metal centre through the
carboxylate and pyridyl nitrogen, three AB spin systems are observed (Figure 2.2).

Figure 2.2 1H NMR spectrum showing the AB spin systems associated with the
formation of a stereogenic centre upon Re(CO)3+ coordination of the PADA ligand,
compound 2.7. Each AB spin system represents two methylene protons, each in a
different chemical environment.

The

13

C NMR spectrum shows a downfield shift of the coordinated carboxylate

carbon atom from approximately 171.3 ppm in MeOH-d4 to 178.6 ppm in dmso-d6 while
the non-coordinated carboxylate is observed at 169.7 ppm, indicating two unique
carboxylate environments within 2.7. This can be rationalized as the loss of electron
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density on the carbonyl group due to the coordination of a positively charged rhenium(I)
tricarbonyl metal core. This provides strong evidence of the formation of the desired
complex.
From this synthetic method, it is possible to acquire large quantities of
bifunctional PADA chelator in order to be used in sequence deconvolution studies and
peptide library construction.

2.2.2 Bispicolylamino Acetic Acid (N,N,N) Rhenium(I) Tricarbonyl Chelate

A chelate holding an overall positive charge was also synthesized in order to
investigate a wide variety of the charge states of rhenium(I) tricarbonyl complexes.
Bispicolylamino Acetic Acid (BPA) has two pyridyl donating nitrogen atoms and an
amine donating group. Like PADA, a free carboxylate is used as a functional group to
attach the compound to a peptide sequence. The synthesis of BPA follows a similar
methodology to the PADA ligand as shown in Scheme 2.5.

Scheme 2.5 Synthesis of BPA (2.8). Reagents: a) 1. NaOH, MeOH, reflux 24 h. 2.
HCl(aq)
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Glycine and picolylchloride hydrochloride, via an SN2 mechanism, form
compound 2.8. The resulting ligand is obtained via trituration with cold benzene. The
product was difficult to crystallize due to high solubility in a variety of solvents from
water to THF. Compound 2.8, under all tested conditions, produced impure red oil. The
product

is

subsequently

coordinated

with

rhenium(I)

tricarbonyl

utilizing

[Et4N]2[ReBr3(CO)3] in methanol to produce 2.9.

Scheme 2.6 Synthesis of Re(CO)3-BPA (2.9). Reagents: a) 2.1, MeOH, reflux.

The coordination of BPA with rhenium(I) tricarbonyl results in downfield shifts
of the pyridyl methylene protons as well as splitting due to the loss of chemical
equivalence in the 1H NMR spectrum. Further, the free carboxylate methylene remains a
singlet due to the formation of an achiral molecule. The pyridyl methylene protons
produce one AB spin system because the protons above and below the plane of the
macrocycle are not equivalent due their inability to freely rotate. The 1H NMR, 13C NMR
spectra and high resolution mass spectrometry provide strong evidence for the desired
coordination compound.
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2.2.3 Nitrilotriacetic Acid (N,O,O) Rhenium(I) Tricarbonyl Chelate

The nitrilotriacetic acid (NTA)-rhenium(I) tricarbonyl complex holds an overall
negative charge.

The chelate allows for the investigation of negatively charged

rhenium(I) tricarbonyl compounds for use in organometallic OBOC peptide libraries.
The chelator contains two carboxylates and an amine nitrogen as potential ligands.

Scheme 2.7 Synthesis of Re(CO)3-NTA (2.10). Reagents a) NaOH(aq), 2.2

The donation of two carboxylate oxygen atoms to the soft rhenium(I) metal centre
is expected to be thermodynamically disfavourable due to the non-polarisable nature of
the ligands. However, in the absence of any other more favourable donating ligands, the
complex is formed in 37% yield from a reaction of nitrilotriacetic acid,
[Re(H2O)3(CO)3]OTf and sodium hydroxide in water.

Initially, the synthesis was

attempted utilizing [Et4N]2[ReBr3(CO)3]. Although 2.10 was observed by 1H NMR
spectroscopy, there was a mixture of sodium and tetraethylammonium counterions
present. The 1H and

13

C NMR spectra show unambiguous evidence of coordination.

High resolution mass spectrometry also shows the expected mass and isotopic signature.
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2.2.4 2-Picolylamino-N,N-2-Hydroxybenzyl Acetic Acid (N,N,O) Rhenium(I)
Tricarbonyl Chelate

The development of a tridentate rhenium(I) tricarbonyl chelate utilizing a phenol
ligand was desirable due to the ligand’s ability to hold a negative charge and therefore
form a neutral complex in conjunction with an amine and pyridyl nitrogen as donating
ligands.

Phenol based chelators have not been utilized extensively in rhenium(I)

tricarbonyl chemistry. The softer Lewis basicity of the phenol ligand, in comparison to
carboxylates, would be expected to form thermodynamically stable complexes with the
metal core, as well as a very lipophilic outer core due to the phenol aromatic systems
involved, which is often desirable in imaging.

The lipophilicity allows access to

hydrophobic binding pockets that are common in enzymes and receptors, allowing for the
rhenium chelate to be a necessary part of the binding affinity of the imaging probe.23
Recently, phenol, amine and aromatic nitrogen bifunctional systems have been
investigated by Lim et al., utilizing pendant alkene, cyano and amine functionalities as
available methods to attach the chelate to a biomolecule with mixed results. 65 While
complexes were successfully formed utilizing the alkene and cyano functionalities, most
likely due to their poor coordination properties, the amine has been shown to
preferentially coordinate over the phenol forming a positively charged complex.
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Figure 2.3 Phenol based (N,N,O) coordination of rhenium(I) tricarbonyl. R = H, CH2CH=CH2, -(CH2)2CN. In these complexes, amines are shown to preferentially donate
electrons to the rhenium(I) tricarbonyl in comparison to the phenol ligand.

However, utilizing a free carboxylate in a bifunctional chelator has not been
investigated previously. One would suspect that a phenol as a Lewis base would be a
more favourable ligand in comparison to a carboxylate due to the difference in
thermodynamic stability. Thus, a synthetic method was developed in order to test this
hypothesis.

Scheme 2.8 Synthesis of PHA (2.13) and Re(CO)3-PHA(2.14). Reagents: a) 1. MeOH
2. NaBH4. b) tert-butyl, benzyl, ethyl bromoacetate or benzyl bromoacetate, NEt3,
MeCN to form 2.12a, 2.12b or 2.12c, respectively c) 2.12a, TFA, DCM. d) 2.2, H2O,
NaOH.
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A reductive amination reaction utilizing salicaldehyde and 2-picolylamine creates
2.11 through a yellow imine intermediate. This compound is then reduced with the
addition of three equivalents of sodium borohydride. Compound 2.11 was purified by
column chromatography. The basic secondary amine in the presence of the acidic phenol
results in a poor yield as the compound does not move cleanly on silica. Isolation and
purification of the imine intermediate followed by reduction did not improve yields. A
reaction with tert-butyl bromoacetate, benzyl bromoacetate or ethyl bromoacetate creates
2.12a, 2.12b, or 2.12c. The low yields of the reactions can be explained by the presence
of a nucleophilic oxygen atom of the phenol functionality.

The tert-butyl ester of

compound 2.12a is then removed utilizing TFA/DCM to form compound 2.13 in 80%
yield. Of note is the presence of the phenol peak in the 1H NMR at a downfield position
of 10-11 ppm for all of the previous compounds. A representative spectra is provided of
compound 2.12a in Figure 2.4.

Figure 2.4 1H NMR spectrum of 2.12a showing the region from approximately 6 ppm to
11 ppm in CDCl3. The appropriate aromatic peaks are visible along with a peak at 10.3
ppm corresponding to the phenol proton.
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The downfield shift of the phenol can be attributed to the unique chemical
environment of the phenol proton as it may interact with the tertiary amine, producing
downfield chemical shift for the phenolic hydrogen. This compound is then coordinated
with rhenium(I) tricarbonyl in methanol. The expectation is that this results in product
2.14 (Scheme 2.8).
Compound 2.14 has been characterized by 1H NMR,

13

C NMR and HRMS.

However, this has led to inconclusive results about the nature of the coordination sphere.
The spectra are unambiguous in that a tridentate complex has been formed due to the
splitting of the methylene protons similarly observed in other chelates.

However,

evidence for coordination of the phenol or the carboxylate group to the metal centre is
inconclusive. In figure 2.5, a comparison between the 1H NMR spectra of compounds
2.13 and 2.14 shows an obvious downfield shift of all aromatic protons upon
coordination. This provides evidence of tridentate coordination utilizing the phenol.

Figure 2.5 A comparison of the 1H NMR spectra obtained from A) un-coordinated
compound 2.13, and B) coordinated compound 2.14, in deuterated methanol. All of the
aromatic peaks shift downfield as a result of the addition of the rhenium(I) tricarbonyl.
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In addition, the coordinated complex 2.14 has been observed to produce a
negative result during the qualitative ferric chloride test for phenol; a positive test results
in a purple solution if a phenol group is present. These results lead to the conclusion that
the phenol is a donating ligand in the coordination sphere. However, there is also a broad
peak at 10-11 ppm in DMSO-d6 which could correspond to an extremely downfield
phenol peak or an upfield carboxylic acid peak. A downfield phenol peak, although
easily explained in uncoordinated compounds due to the presence of a tertiary amine in
close proximity, would not be easy to explain due to the absence of electrons on a
nitrogen which is acting as a coordinating ligand. This further adds to the ambiguity of
the 1H NMR spectra obtained from this compound. Yet, the 13C NMR spectrum provides
evidence that shows a carboxylate shift of 178.5 in DMSO-d6 which is consistent with
coordination of the carboxylate ligand.
Because of the conflicting evidence, a protecting group strategy was utilized to
attempt to unambiguously form a phenol-donating complex. 2.12a was coordinated with
rhenium(I) tricarbonyl in methanol in order to avoid the presence of a free carboxylate.
Initially, this route seemed to produce the desired result, however upon further
investigation by HPLC-ESI, the presence of masses associated with coordinated
compounds containing methyl esters and free carboxylates and no compound containing
the tert-butyl ester. The mechanism of this transformation is unknown. This reaction
was also repeated using a benzyl protected carboxylic acid, 2.12b, and the ethyl protected
carboxylic acid, 2.12c, to the same result. Verification of the formation of a methyl ester
was obtained by 1H NMR spectroscopy. The reaction was also repeated in DMF, in an
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attempt to avoid the trans-esterification.

However, the resulting reaction mixture

contained a major portion of compound 2.14 by HPLC-MS.
Because of these results, it was decided to first attach compound 2.13 to a peptide
chain, and coordinate rhenium(I) tricarbonyl after attachment to a peptide. This process
will be discussed in the next chapter.

2.3 Conclusions

This chapter has outlined the successful synthesis and characterization of three
rhenium(I) tricarbonyl chelates to be utilized in the investigation of organometallic
OBOC peptide libraries.

These chelates represent neutral, positive and negatively

charged compounds that provide a representation of the entire spectrum of rhenium(I)
tricarbonyl chelates. A fourth phenol-based chelate has also been investigated. However,
the coordination of the phenol to the metal core has not been conclusively determined.
This chelator (2.13) can be used, however, to investigate on resin coordination techniques
for OBOC library creation.

2.4 Experimental
2.4.1 General Procedures

All chemicals and solvents were purchased from commercially available sources
and used without further purification. Chemicals were purchased from Sigma Aldrich,
Alfa Aesar or Strem.

Solvents were purchased from Fisher Scientific.

Silica gel
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chromatography was performed using SiliFlash F60 (230-400 mesh) purchased from
Silicycle. Flash silica gel chromatography was performed using a Biotage Isolera Prime
Flash Purification System. Analytical HPLC was preformed utilizing a Waters Sunfire
C18 column 4.6 x 150 mm, 5 µm. The gradient system utilized consists of acetonitrile +
0.1% TFA and water + 0.1% TFA. Ultraviolet absorbance measurements were obtained
utilizing a Waters 2998 Photodiode Array Detector and mass spectra were obtained via
electrospray ionization utilizing a Micromass Quatro Micro LCT mass spectrometer.
NMR data were obtained on a Varian Inova 400 MHz spectrometer or a Varian Mercury
VX 400 MHz spectrometer. Deuturated solvents were purchased from Sigma Aldrich.
Chemical shifts were referenced in respect to residual solvent shifts. High resolution
mass spectrometry, electron impact and electrospray, was done utilizing a Finnigan MAT
8200 or a PE-Sciex API 365, respectively.

2.4.2 Small Molecule Synthesis

[Et4N]2[Re(CO)3Br3], 2.1, was prepared according to a previously published
literature procedure.66

[Re(H2O)3(CO)3]OTf , 2.2, was prepared according to a

previously published literature procedure.67
2-Picolylamino-N,N-diethylacetate (2.3)
To a solution of picolylamine (0.78 mL, 7.6 mmol) in DMF (9.8 mL) at 0 oC,
triethylamine (2.48 mL, 17.7 mmol) was added and allowed to stir for 10 minutes. Ethyl
bromoacetate (0.84 mL, 7.6 mmol) was added dropwise as the solution was allowed to
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stir. The solution turned yellow, and a second portion of ethyl bromoacetate (0.84 mL,
7.6 mL) was added dropwise. The reaction was allowed to stir for two hours at 0 oC.
Subsequently, the reaction was warmed to room temperature and the solvent was
removed in vacuo. The remaining solid was dissolved in 20 mL of ethyl acetate and
filtered. The ethyl acetate in the filtrate was removed in vacuo. The residue was purified
by silica gel chromatography (EtOAc/NEt3, 99:1). After purification, 0.96 g of product
was isolated as yellow oil. (Yield: 45%).

1

H NMR (CDCl3) δ 8.54 (m, 1H), 7.68 (m,

1H), 7.61 (m, 1H), 7.71 (m, 1H), 4.17 (q, 4H, J = 7 Hz), 4.07 (s, 2H), 3.62 (s, 4H), 1.27
(t, 6H, J = 7 Hz).

13

C NMR (CDCl3) δ 171.3, 159.0, 149.2, 136.8, 123.2, 122.3, 60.7,

60.0, 55.0, 14.4. Mass (EI) (m/z) [M]+ calc: 280.1423 obs: 280.1429.
Potassium (2-picolylamino)-N-ethylacetate-N-acetate (2.4)
To a solution of 0.5M KOH in EtOH (1.6 mL, 0.8 mmol) at 0 oC, 2.1 (0.23 g, 0.8 mmol)
was added. The reaction was allowed to stir overnight. The solvent was removed in
vacuo and the solid residue was triturated in diethyl ether. The remaining residue was
dried in vacuo, resulting in 0.14 g of a yellow solid (Yield: 61%).

1

H NMR (CDCl3) δ

8.58 (m, 1H), 7.54 (m, 1H), 7.12 (m, 1H), 7.08 (m, 1H), 4.00 (q, 2H, J = 7 Hz), 3.66 (s,
2H), 3.21 (s, 2H), 3.03 (s, 2H), 1.15 (t, 3H, J = 7 Hz).
(2-picolylamino-N-acetate) (N,N,O) rhenium tricarbonyl-N-ethylacetate (2.5)
To a solution of MeOH (10 mL) and [Et4N]2[Re(CO)3Br3] (0.27 g, 0.35 mmol), 2.4 (0.1
g, 0.39 mmol) was added. The solution was allowed to stir overnight. The solvent was
removed in vacuo to yield as solid residue.

The residue purified by silica gel

chromatography (EtOAc). This yields 0.10 g of white solid (Yield: 53%).

1

H NMR
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(CDCl3) δ 8.84 (m, 1H), 7.96 (m, 1H), 7.51 (m, 1H), 7.46 (m, 1H), 5.28 (d, 1H, J = 15
Hz), 4.45 (d, 1H, J = 17 Hz), 4.37 (d, 1H, J = 15 Hz), 4.32 (d, 1H, J = 17 Hz) 4.31 (q, 2H,
J = 7 Hz), 3.91 (d, 1H, J = 17 Hz), 3.69 (d, 1H, J = 17 Hz), 1.37 (t, 3H, J = 7 Hz)
Potassium 2-picolylamino-N,N-diacetate (PADA) (2.6)
To MeOH (20 mL) picolylchloride hydrochloride (0.68 g, 4.13 mmol) was added and
allowed to stir for 5 minutes. Potassium hydroxide (0.23 g, 4.13 mmol) was added
slowly. The solution begins to turn red and was stirred for 30 minutes; a solid forms. To
a separate solution of MeOH (37.5 mL) and potassium hydroxide (0.65 g, 11.5 mmol),
iminodiacetic acid (0.5 g, 3.75 mmol) was added. After 30 minutes of stirring, the
picolylchloride hydrochloride solution was filtered and added dropwise to the
iminodiacetic acid solution. The reaction mixture was refluxed overnight. The reaction
was allowed to cool to room temperature and was filtered. The methanol of the filtrate
was removed in vacuo and the residue was dissolved in water (10 mL) and washed with
DCM (4 x 10mL). 1 M hydrochloric acid was added to the water solution until neutral
pH was obtained. The water was then removed in vacuo. The remaining residue was
redissolved in anhydrous methanol and filtered. The methanol was removed in vacuo and
the residue was recrystallized in EtOH, yielding 0.45 g of product (Yield: 40%).

1

H

NMR (MeOH-d4) δ 8.59 (m, 1H), 7.85 (m, 1H), 7.84 (m, 1H), 7.39 (m, 1H), 4.48 (s,
2H), 3.71 (s, 4H).

13

C NMR (MeOH-d4) δ 171.3, 153.2, 150.6, 139.3, 135.3, 135.2, 59.5,

58.0. Mass (ES-) [M]- (m/z) calc: 223.0719, obs: 223.0729.
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2-Picolylamino-N,N-diacetate rhenium(I) tricarbonyl (PADA-Re(CO)3) (2.7)
To a solution of MeOH (36 mL) and 2.6 (0.22 g, 0.75 mmol), [Et4N]2[ReBr3(CO)3]
(0.556 g, 0.75 mmol) was added slowly at room temperature. The reaction was stirred
overnight, a white precipitate formed. The reaction mixture was filtered and dried,
resulting in 0.233 g of product. (Yield: 58%)

1

H NMR (DMSO-d6) δ 8.75 (m, 1H),

8.14 (m, 1H), 7.84 (m, 1H), 7.57 (m, 1H), 5.12 (AB, 1H, J = 16 Hz), 4.73 (AB, 1H, J =
16 Hz), 4.53 (AB, 1H, J = 17 Hz), 4.30 (AB, 1H, J = 17 Hz), 4.04 (AB, 1H, J = 17 Hz),
3.63 (AB, J = 17 Hz).

13

C NMR (DMSO-d6): 197.0, 196.9, 196.7, 178.6, 169.7, 159.5,

151.7, 140.3, 125.7, 123.9, 67.8, 67.4, 61.5. Mass (ES+) [M+H]+ (m/z) calc: 517.0022,
obs: 517.0035.
Bispicolylamino acetate (BPA) (2.8)
To a suspension of 2-picolylchloride hydrochloride (0.6 g, 3.6 mmol) in water (10 mL),
NaOH (0.26 g, 6.6 mmol) was added. The 2-picolylchloride hydrochloride dissolved and
became red.

Glycine (0.125 g, 1.6 mmol) was added.

The reaction was refluxed

overnight at 65 oC. The reaction mixture was cooled to room temperature and neutralized
to pH = 7 using 1 M HCl(aq). The resulting solution was then washed with DCM. The
aqueous layer was then removed in vacuo. The resulting residue was triturated with
isopropyl alcohol and filtered. The filtrate was taken and the solvent removed in vacuo.
The resulting residue was triturated with cold benzene and filtered. The filtrate was taken
and the solvent removed in vacuo. This resulted in 0.08 g of brown powder (Yield:
20%). 1H NMR (DMSO-d6): δ 8.49 (m, 2H), 7.77 (m, 2H), 7.25 (m, 2H), 7.25 (m, 2H),
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3.93 (s, 4H), 3.35 (s, 2H).

13

C NMR (CDCl3): δ 174.0, 158.2, 148.6, 137.2, 122.8, 122.6,

59.9, 58.5. Mass (EI+) [M+H]+ (m/z) calc: 257.1164, obs: 257.1159.
Bispicolylamino acetate rhenium(I) tricarbonyl (BPA-Re(CO)3) (2.9)
To a solution of MeOH (20 mL), [Et4N]2[ReBr3(CO)3] (0.10 g, 0.13 mmol) was added
and stirred until it dissolved. 2.8 (0.04 g, 0.13 mmol) was dissolved in MeOH (2 mL)
and added dropwise to the reaction mixture. The reaction was refluxed for 5 hours.
Subsequently, the reaction was cooled to room temperature and the solvent was removed
in vacuo. The resultant residue was recrystallized from methanol. This yielded 0.01 g
product (Yield: 15 %). 1H NMR (CD3OD): δ 8.84 (m, 2H), 7.92 (m, 2H), 7.54 (m, 2H),
7.35 (m, 2H), 5.33 (AB, 2H, J = 17 Hz), 4.98 (AB, 2H, J = 17 Hz), 4.72 (s, 2H).

13

C

NMR (CD3OD): δ 212.7, 212.6, 171.2, 162.5, 153.2, 141.8, 127.1, 124.7, 69.4, 69.1.
Mass (ES+) [M]+ (m/z) calc: 527.0491, obs: 527.0481.
Nitrilotriacetate rhenium(I) tricarbonyl (NTA-Re(CO)3) (2.10)
To a flask containing water (3 mL), nitrilotriacetic acid (0.06 g, 0.3 mmol) was added to
form a suspension. 0.5 M NaOH(aq) (1.8 mL, 0.9 mmol) was added dropwise, resulting in
a clear solution. 0.1 M [Re(CO)3(H2O)3]OTf(aq) (3 mL, 0.3 mmol) was added dropwise
and the reaction was allowed to stir overnight. The solvent was then removed in vacuo.
The residue was then dissolved in IPA and filtered. The filtrate was taken and the solvent
was removed in vacuo. The resulting white powder was triturated in DCM and filtered.
The filtrate was dried, yielding 0.06 g of white powder (37% yield). 1H NMR (CD3OD):
δ 4.21 (s, 2H), 4.03 (AB, 2H, J = 16 Hz), 3.83 (AB, 2H, J = 16 Hz).

13

C NMR (DMSO-
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d6): δ 198.4, 198.3, 178.3, 169.9, 68.0, 63.6. Mass (ES+) [M+H]+ (m/z) calc: 505.9474,
obs: 505.9470.
2-[(2-Picolylamino)methyl]phenol (2.11)
To a round bottom flask of MeOH (4.5 mL), salicaldehyde (0.213 mL, 2 mmol) was
added. The reaction was stirred and 2-picolylamine was added dropwise (0.206 mL, 2
mmol). The reaction immediately became a yellow colour. After stirring for 2 hours,
sodium borohydride (0.0756, 2 mmol) was added in four portions over the course of 1
hour. The yellow colour disappears and the reaction became clear. The solvent was
removed in vacuo. The residue was dissolved in water and extracted into DCM. The
DCM was removed in vacuo and the product was purified by silica gel chromatography
(EtOAc/MeOH, 9:1). This yielded 0.22 g of a translucent oil (51% yield).

1

H NMR

(CDCl3): δ 8.60 (m, 1H), 7.68 (m, 1H), 7.21 (m, 3H), 6.98 (m, 1H), 6.87 (m, 1H), 6.79
(m, 1H), 4.02 (s, 2H), 3.94 (s, 2H).

13

C NMR (CDCl3): δ 158.2, 157.8, 149.4, 136.7,

128.8, 128.6, 122.7, 122.4, 122.3, 119.0, 116.4, 53.1, 51.7. Mass (EI+) [M+H]+ (m/z)
calc: 214.1106, obs: 214.1106.
2-Picolylamino-N,N-2-hydroxybenzyltert-butyl acetate (2.12a)
To a stirred round bottom flask containing MeCN (4.5 mL), 2.11 (0.28 g, 1.3 mmol), tertbutyl bromoacetate (0.19 mL, 1.3 mmol) and triethylamine (0.18 mL, 1.3 mmol) were
added. The reaction was allowed to stir overnight after which it became a dark yellow
colour. The solvent was subsequently removed in vacuo, and the obtained residue was
dissolved in EtOAc. The EtOAc was then filtered to remove an insoluble white powder
and the solvent from the filtrate was removed in vacuo. The product was then purified by
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silica gel chromatography [EtOAc]. The resulting fractions produced 0.13 g of product
as a yellow oil (35% yield). 1H NMR (CDCl3): δ 10.32 (br, s, 1H) 8.58 (m, 1H), 7.68 (m,
1H), 7.35 (m, 1H), 7.20 (m, 2H), 7.02 (m, 1H), 6.91 (m, 1H), 6.79 (m, 1H), 3.96 (s, 2H),
3.89 (s, 2H), 3.32 (s, 2H), 1.48 (s, 9H).

13

C NMR (CDCl3): δ 170.3, 157.7, 157.5, 149.0,

136.8, 129.7, 129.2, 123.3, 122.4, 122.1, 119.0, 116.5, 81.8, 58.9, 56.6, 55.0, 28.1. Mass
(EI+) [M+H]+ (m/z) calc: 328.1787, obs: 328.1775.
2-Picolylamino-N,N-2-hydroxybenzyl, benzyl acetate (2.12b)
This compound was synthesized in an identical fashion to 2.12a, except for the utilization
of benzyl bromoacetate in replacement of tert-butyl bromoacetate. The product was then
purified by silica gel chromatography [EtOAc]. The resulting fractions produced 0.13 g
of product as a yellow oil (25% yield). 1H NMR (CDCl3): δ 10.33 (br, s, 1H), 8.57 (m,
1H), 7.67 (m, 1H), 7.38-7.29 (m, 6H), 7.20 (m, 2H), 6.99 (m, 1H), 6.91 (m, 1H), 6.78 (m,
1H), 5.18 (s, 2H), 4.02 (s, 2H), 3.92 (s, 2H), 3.49 (s, 2H). Mass (EI+) [M]+ (m/z) calc:
362.1630, obs: 362.1643.
2-Picolylamino-N,N-2-hydroxybenzylethyl acetate (2.12c)
This compound was synthesized in an identical fashion to 2.12a, except for the utilization
of ethyl bromoacetate in replacement of tert-butyl bromoacetate. The product was then
purified by sildeica gel chromatography [EtOAc]. The resulting fractions produced 0.13
g of product as a yellow oil (25% yield). 1H NMR (CDCl3): δ 10.29 (br, s, 1H), 8.58 (m,
1H), 7.69 (m, 1H), 7.34 (m, 1H), 7.21 (m, 2H), 7.04 (m, 1H), 6.91 (m, 1H), 6.79 (m, 1H),
4.20 (q, 2H, J = 7 Hz), 3.99 (s, 2H), 3.91 (s, 2H), 3.43 (s, 2H), 1.28 (t, 3H, J = 7 Hz).
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2-Picolylamino-N,N-2-hydroxybenzyl acetate (2.13)
To a flask containing DCM (5 mL), 2.12a (0.48 g, 1.4 mmol) was added producing a
yellow solution. TFA (5 mL) was added dropwise and immediately turned the solution
clear. The reaction was stirred for 3 hours and the solvent was removed in vacuo. The
resulting residue was purified by flash silica gel column chromatography (EtOAc/MeOH,
8:2). The pure fractions produced 0.31 g of product as a white powder (80% yield). 1H
NMR (CD3OD): δ 8.58 (m, 1H), 7.83 (m, 1H), 7.48 (m, 1H), 7.38 (m, 1H), 7.24 (m, 2H),
6.85 (m, 2H), 4.31 (s, 2H), 4.29 (s, 2H), 3.56 (s, 2H).

13

C NMR (CD3OD): δ 171.8,

158.0, 154.2, 150.5, 139.1, 133.0, 132.1, 125.2, 125.1, 121.1, 119.6, 116.9, 59.4, 57.1,
56.4. Mass (EI) [M]+ (m/z) calc: 272.1161, obs: 272.1149
2-Picolylamino-N,N-2-hydroxybenzyl acetate rhenium(I) tricarbonyl (PHA-Re(CO)3)
(2.14)
To MeOH (20 mL) in a round bottom flask, [Et4N]2[ReBr3(CO)3] (0.101 g, 0.13 mmol)
was added. The solution was stirred for 10 minutes until the solution went clear. 2.13
(0.04 g, 0.13 mmol) was added. The solution was stirred under reflux for 5 hours. The
solution was allowed to cool to room temperature and the solvent was removed in vacuo,
producing a white powder.

The powder was triturated in water and filtered.

The

resulting filtrand was dried in vacuo producing 0.02 g of a white powder (20% yield). 1H
NMR (DMSO-d6): δ 10.17 (br s, 1H) 8.78 (m, 1H), 8.10 (m, 1H), 7.13 (m, 1H), 7.57 (m,
2H), 7.29 (m, 1H), 6.98 (m, 1H), 6.91 (m, 1H) 4.82 (AB, 1H, J = 16 Hz), 4.76 (AB, 1H, J
= 13 Hz), 4.61 (AB, 1H, J = 13 Hz), 4.39 (AB, 1H, J = 16 Hz), 4.23 (AB, 1H, J = 17 Hz),
2.99 (AB, 1H, J = 17 Hz) .

13

C NMR (DMSO-d6): δ 178.5, 159.3, 156.1, 151.8, 140.3,
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133.4, 130.5, 125.7, 124.0, 119.1, 119.0, 115.9, 67.3, 65.6, 60.23. Mass (ES+) [M+Na]+
(m/z) calc: 565.0385, obs: 565.0362.
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Chapter 3: Investigation into the Fragmentation of Organometallic
Peptides
3.1 Introduction

In order to develop organometallic OBOC (one-bead, one-compound) peptide
libraries, investigation of an amino acid sequencing method is necessary. Because of the
nature of OBOC libraries, the identity of the compound present on a specific bead is
unknown as OBOC libraries are non-spatially addressable. As such, the synthesis of
organometallic peptides and the examination of their fragmentation patterns by to
MALDI tandem mass spectrometry are investigated herein.

3.1.1 Peptide Synthesis

The synthesis of peptides often utilizes a well known methodology involving the
use of orthogonal protecting groups and the sequential addition of amino acids on solid
polymer support resin, known as solid phase peptide synthesis. This technique was
initially reported by Merrifield in order to overcome difficult and time consuming
solution phase peptide synthesis.68 The most common technique in solid phase synthesis
utilizes an Fmoc (fluorenylmethyloxycarbonyl) protecting group for the backbone amines
of the amino acids. These groups are base labile and removed with piperidine in DMF.
The side chains of the amino acids are protected with a variety of acid-labile groups, the
identity of which depends on the nature of the amino acid.

Common side-chain

protecting groups include Boc (tert-butoxycarbonyl) for amines, tert-butyl ethers for
alcohols and tert-butyl esters for carboxylic acids, among many others.
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The synthesis of peptide sequences on a solid polymer support follows an iterative
procedure of addition and deprotection of amino acids. First, an Fmoc-protected amino
acid is added to the resin through a nucleophilic acyl substitution reaction. The free
amine on the resin and the carboxylate of the Fmoc-amino acid react to form a peptide
(amide) bond. The Fmoc group is necessary in order to avoid multiple additions of
amino acids to the peptide chain. However, this reaction is slow due to the relative
stability of carboxylates in comparison to amides and the moderate nucleophilicity of
amines. As such, the addition of coupling agents is necessary in order to increase the rate
of this reaction (Scheme 3.1).

Scheme 3.1 A diagram of the removal of an Fmoc group and the addition of a second
amino acid to a resin bound amino acid. This process is repeated until the desirable
peptide is synthesized.

After the addition of the Fmoc-amino acid, the removal of the Fmoc group from
the peptide backbone is accomplished through the use of most commonly
piperidine/DMF. These two steps can then be repeated with different Fmoc-amino acids
such that the desired peptide sequence can be created.
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After a peptide has been synthesized, the side-chain protecting groups are
removed via the addition of acid, most commonly TFA (trifluoroacetic acid).

The

reagent used to cleave the acid-labile side chain protecting groups usually contains a
small percentage of scavenging agents such as water, phenol or triisopropylsilane. The
purpose of the addition of the scavenging agents is to react with electrophiles created
from the cleavage of protecting groups, such as t-butyl cations. This is necessary in order
to avoid the reaction of these electrophiles with the peptide chain.
There are a wide variety of solid-support resins available to be used. The general
formulation of a solid-support involves the presence of an insoluble polystyrene crosslinked backbone on which PEG (polyethylene glycol) groups are attached. The PEG
groups contain a functional group which a peptide can be built upon; the type of
functional group depends on the type of resin used, and their purpose is primarily to
provide a method to remove the peptide from the resin after complete synthesis.
Utilizing standard Fmoc solid phase peptide synthesis procedures, organometallic
peptides can be synthesized and mass spectrometry can be used to investigate amino acid
sequencing protocols for organometallic OBOC peptide libraries.

3.1.2 Mass Spectrometric OBOC Sequencing Methods

A number of mass spectrometric methods have been utilized in order to
deconvolute compounds present in OBOC libraries in addition to Edman degradation.
Ladder peptide synthesis, partial Edman degradation-MS (PED-MS), tagging techniques
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and tandem mass spectrometry have all proven to be useful techniques for identification
of bioactive compounds.
Ladder peptide synthesis involves an additional synthetic step during OBOC
library synthesis. After each amino acid coupling, a small percentage of the peptide
chains are “capped” such that subsequent amino acid additions do not react with the
“capped” molecules.69 After screening an OBOC library, mass spectrometry can identify
all peptide sequences present on bead, and the difference between the peaks,
corresponding to terminated peptide sequences has been shown to reveal the identity of
the sequence.70 However, the presence of truncated peptides, acting as contaminants
during library screening, is not desirable.
PED-MS is similar to ladder peptide synthesis as a single OBOC bead will
contain a series of truncated peptide sequences. Edman degradation is performed on a
bead-bound peptide and with the addition of a percentage of capping agent. A small
amount of peptide sequences will be terminated by the capping agent after each
degradation step. Fmoc, Nic-OSu71 and phenyl thiocyanate72 groups have been shown to
be useful for this strategy. The beads are then analyzed by mass spectrometry, and the
difference in mass between truncated peptides allows for identification. The benefit of
this technique over ladder synthesis is that all truncation is done after library screening.
Recently, Thakkar et al. utilized PED-MS to sequence peptoid compounds from an
OBOC library using Fmoc capping groups for sequence termination.73 Additionally,
PED-MS has been used to identify peptide-glycoprotein interactions from OBOC library
screening.74 The main drawback associated with PED-MS is the requirement of peptides
to contain free N-terminal amines.
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Figure 3.1 The general procedure of peptide deconvolution through the use of ladder
synthesis and partial Edman degradation coupled with mass spectrometry.

Tagging methodologies are also popular techniques in screening OBOC libraries.
A small percentage of the bead will contain a tag which can reveal the identity of the
“hit” compound from an OBOC library. This technique is commonly used in small
molecule OBOC libraries because of the difficulty in identifying a large number of small
molecules as first reported by Liu et al.75

Additions of amino acids on the bead

corresponding to an addition of specific group to the small molecule, allow a small
molecule to be identified by peptide mass spectrometry. Moreover, this technique has
been utilized to test and identify cyclic peptides acting on breast cancer cell lines from
OBOC libraries.76 Additionally, the identification of isobaric amino acids is possible
because the corresponding amino acid tag can be arbitrarily assigned to provide
maximum possible information.

The problem of interference between the tagging

sequence and the bioactive compound has largely been overcome by the creation of
biphasic solid phase support which allows for the synthesis of the tag on the interior of
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the bead, and the bioactive compound on the exterior (Figure 3.2).77 Limitations of such
a procedure include an increase in synthetic steps and expense as well as the potential for
decreased detectability of peptide due to the smaller amounts present on the bead.

Figure 3.2 The utilization of linear peptides to code for bioactive cyclic peptides on a
single bead. The inner core of the bead holds the tagging linear peptide and can be
sequenced by MS methods in order to identify the cyclic tripeptide.

Tandem mass spectrometry is also an important technique that involves the
ionization of peptides utilizing most commonly ESI (electrospray ionization) or MALDI
(matrix-assisted laser desorption/ionization) methods. Electrospray ionization commonly
produces multiply charged ions and can be used in conjunction with liquid
chromatography,78 while in utilizing MALDI the singly charged mass ion is observed.
The ions formed are then separated based on their m/z ratio and subsequently fragmented.
The ionic fragments that are produced can reveal information about the connectivity of
the peptide. Tandem mass spectrometry is a very convenient method for OBOC peptide
sequencing because it is able to quickly and economically provide sequences in a
relatively high-throughput manner. The use of a UV MALDI laser to cleave peptides
attached to beads via a photolinker,79 as well as the sequencing of peptides through
MALDI laser cleavage combined with tandem mass spectrometry80 have been reported.
Additionally, a combination of ladder synthesis and on-bead mass spectrometric
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sequencing has also been reported.81 However, sequencing of OBOC libraries containing
octa- and pentapeptides via both on-bead and solution-phase MALDI tandem mass
spectrometry has revealed an increase in spectrum quality via solution phase analysis.82
There are a wide-variety of OBOC sequencing methods available in the
identification of bioactive compounds on “hit” beads. However, when developing an
amino acid sequencing method applicable to organometallic peptides, various other
considerations need to be examined. The properties of the imaging entity surrogate; the
presence of rhenium(I) tricarbonyl chelates need to be taken into account as well as the
position of the chelate on the N-terminal amine of the peptide chain. Tandem mass
spectrometry was chosen as a tool to further investigate the deconvolution of
organometallic OBOC peptide libraries.

3.1.3 Tandem Mass Spectrometry and Peptide Fragmentation

An investigation to observe the affects of the addition of the organometallic
species affects the ionization or fragmentation of peptides is necessary in order to
determine an appropriate method for amino acid sequencing. Further, if the chelate itself
forms fragmentation products, these need to be identified. A variety of MALDI spectra
of rhenium(I) tricarbonyl metal cores have previously been reported. In an investigation
of porphyrin rhenium(I) tricarbonyl compounds by Toganohn et al., MALDI results have
shown a variety of prominent mass peaks in the spectrum of the precursor depending on
the compound. The most common peak reported is the result of the loss of all three
carbonyl ligands resulting in a [M-3(CO)]+ peak.83 Conversely, the MALDI results from
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a vitamin B12 compound modified with a rhenium(I) tricarbonyl chelate, show the
presence of primarily signals assigned to [M-CO]+ and [M-2(CO)]+, in addition to [M]+
peak.84 In these cases, carbonyls were readily discharged from the molecule, depending
on the type of coordination environment. If this is observed for peptide sequencing
applications, it could complicate organometallic peptide sequencing due to a number of
low intensity peaks as well as removal of metallic carbonyls in fragmentation. Therefore,
the identity of peaks might be ambiguous if it is unknown how many carbonyls the
fragment contains. From these reported results, it would seem that the removal of
carbonyls in MALDI mass spectrometry is highly dependent on the coordination
environment of the metal core and therefore it is prudent to investigate the fragmentation
properties of rhenium(I) tricarbonyl tridentate chelates.
Fragmentation though mass spectrometry for determining amino acid sequences
in peptides is dependent on the ability of peptides to produce well defined series of
peptide fragments which correspond to individual amino acids (Figure 3.3).

Figure 3.3 A generic tetrapeptide holding a positive charge on the N-terminus. This
compound is fragmented through CID (collision-induced dissociation) The a2 and b2
fragments are N-terminal fragments while the x2 and y2 fragments are C-terminal.
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The types of fragments shown above can be classified into two types of peptide
fragments. The a and b fragments maintain a charge on the N-terminus of the peptide.
Conversely, the x and y fragments maintain a charge on the C-terminus of the peptide.
The fragmentation pathways are not fully understood, however it is known that b ions in
have a protonated oxazolone structure85 and are an intermediate in the creation of a
fragments.86 The y ions have been shown to be truncated peptide ions as shown in figure
3.3.87 A peptide would be expected to produce a series of fragments corresponding to
each peptide bond. The difference in mass between two fragments from the same series
can be used to identify an amino acid based on the known mass of the side chain. This
method is known as de novo peptide sequencing,88 and has been shown to be highly
applicable to small peptide sequences.89
Theoretically, this process is very simple and straight forward.

However, a

problem associated with peptide fragmentation is that the fragmentation patterns are
sequence dependent. The source of the diversity in fragmentation patterns is that amino
acids have a wide variety of side chains which have dramatically different abilities to
accept and donate protons. The mobile proton theory is the most complete explanation of
peptide fragmentation in tandem mass spectrometry. The theory states that during the
initial ionization, basic residues such as amines accept protons from the matrix. During
CID, the protons can move to various other parts of the peptide chain such as an amide
nitrogen or oxygen, which leads to fragmentation.90

Therefore, the fragmentation

patterns depend on where and in which ratios the peptide initially becomes protonated,
which residues are in close enough physical proximity to receive the proton after
collisions with gas molecules and which are the most energetically favourable residues to
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receive the proton. Thus, the process of peptide fragmentation involves a myriad of
pathways and potential pathways which need to be understood if the presence or absence
of a fragment is to be rationalized. Attempts to simplify de novo sequencing have been
accomplished by the addition of isotopic signatures on the terminal of the peptide
sequence in order to more easily identify N- and C-terminal fragments. A recent example
of isotopic tagging involves the coupling of bromo pyridyl derivatives to the N-terminal
of the peptide sequence and allows for identification of the N-terminal fragments via the
bromine isotopic ratio.91 Interestingly, this technique can also be applied in rhenium(I)
tricarbonyl organometallic OBOC libraries because of the chelates are on the N-terminus
and rhenium has a distinct isotopic ratio.
Because peptide fragmentation is not fully predictable, and the identity of the
amino acids present as well as the three dimensional conformation of the peptide are all
factors in obtaining mass spectra, the effect of the rhenium(I) tricarbonyl chelates also
needs to be taken into account. It is possible that the presence of the organometallic may
affect proton movement such that there are few favourable fragmentation pathways, and
it is also possible that the type of chelate present can produce dramatically different
fragments. Proteins and peptides are often deconvoluted with the assistance of protein
databases, whereby fragmentation patterns are compared to thousands of known database
entries.92

However, due to the presence of rhenium(I) tricarbonyl chelates in the

organometallic peptides, these techniques are not available.

Therefore, variables

associated with organometallic peptide fragmentation need to be addressed in order to
utilize MALDI tandem mass spectrometry for sequencing organometallic peptides in
OBOC libraries.
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3.2 Results and Discussion

This chapter will outline the investigation of the synthesis and fragmentation
patterns of peptides with N-terminal rhenium(I) tricarbonyl chelates. Firstly, the peptide
synthesis and coupling of the organometallic will be discussed. Secondly, the results of
MALDI TOF/TOF tandem mass spectrometry with organometallic peptides will be
shown. Thirdly, the adaptation of these techniques to OBOC peptide library screening
conditions is investigated herein.

3.2.1 Organometallic Peptide Synthesis

The synthesis of organometallic peptides proceeds through standard Fmoc solid
phase peptide synthesis protocols, as discussed previously. The peptide that was chosen
to test the influence of a rhenium(I) tricarbonyl chelate on peptide fragmentation,
compound 3.1, is a compound which has previously been reported to produce fully
sequencable fragmentation patterns utilizing MALDI TOF/TOF mass spectrometry
(QATDKFTF-NH2). The coupling of the organometallic rhenium(I) tricarbonyl was
shown for PADA, BPA, and NTA compounds (Scheme 3.2).
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Scheme 3.2 Synthesis of organometallic peptides. Reagents: a) 20% piperidine in
DMF b) HBTU, DIPEA, rhenium(I) tricarbonyl chelate in DMF. Rhenium(I)
tricarbonyl chelates 2.7, 2.9 and 2.10 were coupled onto the N-terminus of 3.1 to produce
3.2, 3.3 and 3.4, respectively.

With the peptides synthesized, the Fmoc is removed under standard conditions,
and the organometallic chelate is coupled to the N-terminus utilizing standard amino acid
coupling conditions of HBTU, DIPEA and the chelate in DMF. This is the benefit of
utilizing bifunctional chelates with a free carboxylic acids; the chemistry of adding a free
carboxylic acid to an amine is well-known and high yielding. This results in three
organometallic peptides, 3.2, 3.3 and 3.4, which contain three different rhenium(I)
tricarbonyl chelates on the N-terminus, neutral, positive and negative respectively. These
compounds were purified by HPLC (high-performance liquid chromatography) and their
identity confirmed by mass spectrometry.
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The last organometallic peptide to be synthesized involves the phenol-based
chelator discussed in the previous chapter. The PHA chelate (2.14) proved to be of an
ambiguous coordination sphere; it is unclear if the phenol or the carboxylate is donating
electrons to the metal core. Therefore, an attempt to couple 2.14 to the N-terminus of 3.1
was made under identical conditions as shown in Scheme 3.2. HPLC analysis showed
that no reaction had taken place, providing evidence for carboxylate-based coordination
to the rhenium(I) tricarbonyl core. Therefore, an alternate method of synthesizing the
PHA-organometallic peptide was undertaken utilizing on-resin coordination.
The uncoordinated PHA chelator (2.13) coupled to the peptide compound with a
free N-terminus. Potential problems associated with this process are mainly the fact that
the phenol group remains unprotected during this process. During the activation of the
chelate carboxylic acid, there is potential that the phenol group, being a nucleophile, can
attack the acyl position producing an ester.

Scheme 3.3 A potential reaction during the activation of the carboxylate of 2.13 with the
coupling reagent HBTU. The phenol nucleophile might be expected to form a seven
membered cyclic ring system through intramolecular nucleophylic acyl substitution of the
activated ester.
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However, the potential cyclic compound shown (Scheme 3.3), might also be
susceptible to attack by a nucleophile by the amine of the peptide backbone. Regardless,
the PHA chelator was coupled onto the N-terminus of compound.

By HPLC, this

reaction produced the desired product 3.5, and subsequently [Et4N]2[Re(CO)3Br3] was
added in a DMF/MeOH mixture with DIPEA to produce the desired organometallic
peptide shown below. This product was then purified by preparative HPLC and 3.6 was
identified by mass spectrometry.

Scheme 3.4 Synthesis of 3.6. Reagents: a) 20% piperidine in DMF. b) HBTU,
DIPEA, 2.13 in DMF. c) [Et4N]2[Re(CO)3Br3], DIPEA, in MeOH/DMF. Synthesis of
Re(CO)3-PHA-QATDKFTF (3.6) proceeds through on an on resin coordination
methodology.
With four organometallic rhenium(I) tricarbonyl peptides with unique chelates
synthesized, the peptides were removed from resin, as well as the side chain protecting
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groups deprotected, utilizing Reagent K, a cleavage solution consisting of 95% TFA:
2.5% H2O : 2.5% TIS over the course of three hours. This results in solution phase
peptides containing a C-terminal amide due to the Rink Amide resin. The stability of the
resultant cleaved and deprotected organometallic peptides was investigated by analytical
HPLC. 3.2 (Re(CO)3-PADA), 3.3 (Re(CO)3-BPA) and 3.6 (Re(CO)3-PHA) peptides
show no decomposition of the chelate and high conversion rates of chelate coupling.
However, 3.4 (Re(CO)3-NTA) shows the desired product, the peptide with the chelator
(loss of rhenium(I) tricarbonyl) and the peptide with a free N terminus (3.1) (Figure 3.4).

Figure 3.4 Crude HPLC UV trace of Re(CO)3-NTA-QATDKFTF-NH2 (3.4) after
cleavage from resin. The major peak at 9.90 min represents the desired product with an
m/z 1399. The two peaks at 3.91 and 5.58 min show an observed mass of m/z 956 and
1129 which correspond to the H-QATDKFTF-NH2 and NTA-QATDKFTF-NH2,
respectively.

It is not surprising that the least stable chelate observed is the Re(CO)3-NTA
compound (3.4), which contains two donating carboxylates as well as formally holding a
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negative charge.

The increase in electron density as well as the decrease in steric

hindrance associated with absence of an aromatic system might produce a metal centre
with decreased stability towards highly acidic conditions. Therefore, because of the
apparent decomposition of 3.4 as shown by HPLC, its use as a chelate in a library is not
possible due to the absence of a viable purification method when screening a library.
Nevertheless, all of the desired organometallic peptides were purified by semi-preparative
HPLC, resulting in pure white solids as products. Desired products were identified by
ES+ and MALDI mass spectrometry.
Through coupling rhenium(I) tricarbonyl chelates to the N-terminal amines of the
peptide QATDKFTF, the organometallic PADA, BPA and NTA peptides were created.
A second method of on-resin coordination was utilized to synthesize the organometallic
PHA peptide. The fragmentation patterns of these organometallic peptides are then
investigated utilizing MALDI TOF/TOF mass spectrometry.

3.2.2 MALDI Tandem Mass Spectrometry

In order to investigate the viability of MALDI tandem mass spectrometry as a
method to deconvolute N-terminal organometallic peptides, initial MALDI studies were
undertaken on purified organometallic peptides.
The organometallic peptides were dissolved in water and mixed with a solution of
CHCA (trans-α-cyano-4-hydroxycinnamic acid).

The solution is then spotted on a

MALDI plate and is allowed to slowly evaporate resulting in the organometallic peptide
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and the CHCA co-crystallized. The matrix absorbs UV light from a laser resulting in
ablation and the transfer of a proton to the peptide, which can then be detected. There are
many known matrices; however CHCA has been reported to be the most useful matrix for
short peptides. The mass spectrum obtained shows the expected mass peaks for all of the
organometallic peptides, with the associated rhenium-185/187 isotopic signature.

Figure 3.5 MALDI MS precursor ion spectrum for 3.2. The organometallic peptide has
the expected rhenium 185/187 isotope ratio. [M+H]+ m/z calc: 1432.49 obs: 1432.50
(rhenium-187 peak).

The desired mass is then selected for further fragmentation. Both rhenium 185
and rhenium 187 peaks were selected for fragmentation. The results of these MS/MS
spectra indicated that despite the increased intensity of the rhenium-187 peak, when the
rhenium-185 peak is selected, the N-terminal fragments are easily and unambiguously
identified due to the isotopic signature present in the MS/MS spectrum. This isotopic
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“doublet” is not obvious in the rhenium-187 tandem mass spectrum. The product ion
spectrum was obtained for the Re(CO)3-PADA-QATDKFTF-NH2 (3.2) (Figure 3.6).

Figure 3.6 The product ion spectrum of compound 3.2. The corresponding assignments
of b and y series can be seen at the top of the figure. The identity of amino acids is
determined based on the difference between the m/z in two adjacent peaks of the same
series.

The rhenium-containing peptide chain gives a well defined fragmentation pattern
that can be used to deconvolute the amino acid sequence.

There are a number of

identifiable fragment series present in the spectrum; the b and y series of fragments are
the most abundant as they form a complete series where all amino acid fragments are
present. The b1 fragment is the most intense peak in the spectrum, making it the most
favourable fragmentation pathway for this particular peptide. A table of the identifiable b
and y fragments is shown below:
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Table 3.1 Fragment assignments from series b and y of the product ion spectrum of
compound 3.2. [M+H]+ m/z = 1430.5 (rhenium-185 peak)
Series

b series

y series

Label

b0
b1
b2
b3
b4
b5
b6
b7
b8
y1
y2
y3
y4
y5
y6
y7
y8

Fragment

Peak
(m/z)

Difference
between
peaks (m/z)

Amino Acid
Assignment

RE-PADA+NH3
RE-PADA-Q
RE-PADA-QA
RE-PADA-QAT
RE-PADA-QATD
RE-PADA-QATDK
RE-PADA-QATDKF
RE-PADA-QATDKFT
RE-PADA-QATDKFTF
NOT OBSERVED
TF
FTF
KFTF
DKFTF
TDKFTF
ATDKFTF
NOT OBSERVED

492.3
603.1
674.2
775.2
890.3
1018.3
1165.4
1266.4
1413.5

110.8
71.1
101.0
115.1
128.0
147.1
101.0
147.1

Glutamine
Alanine
Threonine
Aspartic Acid
Lysine
Phenylalanine
Threonine
Phenylalanine

266.1
413.2
541.3
656.4
757.5
828.5

147.1
128.1
115.1
101.1
71.0

Phenylalanine
Lysine
Aspartic Acid
Threonine
Alanine

The peptide is sequenced by obtaining the difference between two adjacent peaks
of the same series (Figure 3.7).

Figure 3.7 Two adjacent peaks, b4 and b5, from the product ion spectrum of compound
3.2. The rhenium isotopic ratio can clearly be seen in each of the peaks, verifying the
assignment of their identities as N-terminal fragments.
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The difference of the two peaks corresponds to a mass of 128.1 Da which
corresponds to a lysine residue. Figure 3.8 is also an illustration of the rhenium isotopic
pattern present in the tandem mass spectrum.
The co-crystallization and MALDI tandem mass spectrometry procedures were
repeated with all of the organometallic peptides and produced product ion spectra for all
of the organometallic peptides (Figure 3.8).

Figure 3.8 The product ion spectra of compounds 3.2 (PADA), 3.3 (BPA), 3.4 (NTA)
and 3.6 (PHA). The effects of different rhenium(I) tricarbonyl chelates can be seen in the
fragmentation patterns and intensities of each spectra.
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From the resultant fragmentation patterns, the correct amino acid sequences of all
of the peptides could be obtained. However, there is a considerable variation in the
observed fragmentation patterns and intensities associated with different chelates on the
N-terminus of the exact same peptide sequence.
It is apparent that the presence of a charged chelate has a large impact on the
fragmentation patterns of the peptide. The Re(CO)3-NTA peptide shows a significant
decrease in observable fragments and intensity for all but the b4 ion which has an m/z of
859.2. There are no complete series present in this spectrum, roughly half of the b and
half of the y series are clearly distinguished (Table 3.2).
Table 3.2 Fragment assignments from series b and y of the product ion spectrum of
compound 3.4. The masses of the b8 and y8 ions can be determined because of the known
mass of the peptide and the N-terminal chelate. [M+2H]+ m/z = 1397.5 (rhenium-185
peak).
Series

b
series

y
series

Label

b0
b1
b2
b3
b4
b5
b6
b7
b8
y1
y2
y3
y4
y5
y6
y7
y8

Fragment

NOT OBSERVED
NOT OBSERVED
NOT OBSERVED
RE-NTA-QAT
RE-NTA-QATD
RE-NTA-QATDK
RE-NTA-QATDKF
RE-NTA-QATDKFT
NOT OBSERVED
NOT OBSERVED
NOT OBSERVED
NOT OBSERVED
KFTF
DKFTF
TDKFTF
ATDKFTF
NOT OBSERVED

Peak
(m/z)

Difference
between
peaks (m/z)

Amino Acid
Assignment

744.2
859.2
987.3
1134.3
1235.3
1382.4

115.0
128.1
147.0
101.0
147.1

Aspartic Acid
Lysine
Phenylalanine
Threonine
Phenylalanine

541.3
656.4
757.4
828.5
956.5

115.1
101.0
71.1
128.0

Aspartic Acid
Threonine
Alanine
Glutamine
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From these two series it is possible to deconvolute the identity of the sequence.
Despite the fact that the sequence was successfully obtained, the results cast doubt on the
versatility of utilizing this chelate with a wide variety of unknown peptide sequences.
The de novo sequencing of peptides is significantly simplified when the compound is of
known connectivity, as one would expect. Furthermore, in the precursor mass spectrum,
approximately 50% decomposition of the chelate is also observed. This is potentially the
result of two mechanisms.

Firstly, the compound might be unstable to the co-

crystallization matrix, as CHCA is an acid and 3.4 shows limited stability to TFA.
Secondly, this might be a result of the ionization process itself. Decomposition occurs
with the transfer of protons to the organometallic peptide. Unfortunately, the combined
lack of stability to TFA, the decomposition during MALDI and poor fragmentation
suggest that these chelates are unsuitable for OBOC library screening. The negative
chelate may be the cause of the poor fragmentation in a positive mass spectrometry
experiment. A potential solution to this problem would be to utilize a negative mass
spectrometry analysis. However, this was not pursued due to the fact that the matrix
remains the same in the negative experiment and will lead to decomposition, in addition
to the lack of TFA stability.
Conversely, 3.3 holds a positive charge and if the negative charge has a major
contribution to the poor fragmentation the of Re(CO)3-NTA peptide, it is expected that
the positive charge would produce many high intensity fragments due to increased
conversion of peptide to gas phase ion. A similar result was obtained recently by Cydzik
et al. using positively charged tetraethylammonium N-terminal peptides to produce more
intense fragments.93 Indeed this is what is observed with the Re(CO)3-BPA peptide. The
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entire b and a series which both correspond to N-terminal charge species are present.
This is not surprising because the N-terminus of the peptide contains a positive charge.
There are also no observable y series fragments that correspond to a C-terminal charged
fragment. This can be rationalized by the fact that y series fragments generally require
the movement of the additional proton added by the matrix to the C-terminus. However,
since Re(CO)3-BPA-QATDKFTF-NH2 is already positively charged it does not gain a
proton from the matrix, as verified by the mass of the precursor peaks. The presence of
every a series ion is somewhat unique in tandem mass spectrometry utilizing collisioninduced dissociation and rarely reported (Table 3.3).
Table 3.3 Fragment assignments from series b and a of the product ion spectrum of
compound 3.3. The masses of the b8 and a8 ions can be determined because of the known
mass of the peptide. The relationship between the a and b series is the loss of a carbonyl,
m/z = 28. [M]+ m/z = 1463.6 (rhenium-185 peak).
Series

Label

b0
b1
b2
b3
b series b4
b5
b6
b7
b8
a0
a1
a2
a3
a4
a series a5
a6
a7
a8

Fragment

Peak
(m/z)

Difference
between
peaks (m/z)

Amino Acid
Assignment

RE-BPA+NH2
RE-BPA-Q
RE-BPA-QA
RE-BPA-QAT
RE-BPA-QATD
RE-BPA-QATDK
RE-BPA-QATDKF
RE-BPA-QATDKFT
NOT OBSERVED
NOT OBSERVED
RE-BPA-Q-CO
RE-BPA-QA-CO
RE-BPA-QAT-CO
RE-BPA-QATD-CO
RE-BPA-QATDK-CO
RE-BPA-QATDKF-CO
RE-BPA-QATDKFT-CO
NOT OBSERVED

527.1
638.2
709.2
810.3
925.3
1053.4
1200.4
1301.5
1448.7

111.1
71.0
101.1
115.0
128.1
147.0
101.1
147.2

Glutamine
Alanine
Threonine
Aspartic Acid
Lysine
Phenylalanine
Threonine
Phenylalanine

610.2
681.2
782.2
897.3
1025.4
1172.4
1273.4
1420.5

71.0
101.0
115.1
128.1
147.0
101.0
147.1

Alanine
Threonine
Aspartic Acid
Lysine
Phenylalanine
Threonine
Phenylalanine
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Because of the high intensity, complete fragment series and relative stability of
BPA peptide (3.3) to acidic conditions, BPA is a candidate for use in OBOC peptide
libraries. A potential problem in sequencing unknown peptides would be the large
number of N-terminally charged fragments might make de novo sequencing difficult due
to an increasing probability of inappropriate determinations of structure.
Like the Re(CO)3-PADA peptide, Re(CO)3-PHA-QATDKFTF-NH2 (3.6), also
forms neutral complexes with rhenium(I) tricarbonyl. As such, one would expect similar
fragmentation patterns and peak intensities. Although the PADA and PHA chelates
produce the most similar mass spectra of any of the chelates, there are a number of
differences. While the b1 peaks for both 3.2 and 3.6, m/z 603.1 and 651.2, respectively,
are both the base peaks for each spectrum, the relative intensities of peaks present in the
PHA spectrum are generally lower in comparison to the dominant b1 fragment,. There is
a full complement of b series fragments that were used to successfully sequence the
peptide. However, there was only one identifiable y peak, y7 with an m/z = 828.5.
Table 3.4 Fragment assignments from series b of the product ion spectrum of compound
3.6. The masses of the b8 ion can be determined because of the known mass of the
peptide. [M+H]+ m/z = 1478.5 (rhenium-185 peak).
Series

Label

b0
b1
b2
b3
b series b4
b5
b6
b7
b8

Fragment

Peak
(m/z)

RE-PHA-NH3
RE-PHA-Q
RE-PHA-QA
RE-PHA-QAT
RE-PHA-QATD
RE-PHA-QATDK
RE-PHA-QATDKF
RE-PHA-QATDKFT
NOT OBSERVED

540.1
651.2
722.2
823.3
938.3
1066.4
1213.4
1314.5
1461.5

Difference
between
peaks (m/z)
111.1
71
101.1
115
128.1
147
101.1
147

Amino Acid
Assignment

Glutamine
Alanine
Threonine
Aspartic Acid
Lysine
Phenylalanine
Threonine
Phenylalanine
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Perhaps the most interesting aspect of the behaviour of PHA in the daughter ion
spectrum is the presence of chelate fragmentation patterns. These fragments generally
consist of a loss of an m/z of 106 when compared to b fragments. These peaks also
contain the characteristic rhenium isotopic signature indicating the presence of rhenium
in the fragment. This shows that these fragments must be N-terminal in nature. Further,
these peaks, although not present in a full series, are found over a very large mass range.
For example, a peak observed at m/z 1374.5 is 106.0 less than the [M+H]+ of m/z 1480.5.
Furthermore, there is a loss of 106.0 from the b1 ion of m/z 651.2. Because of the
presence of the mass loss throughout the entire series of b ions, as well as some of the a
ions, the loss of 106.0 can only be explained by a fragmentation of the chelate (Scheme
3.5).

Scheme 3.5 The proposed fragmentation mechanism of the phenol-based chelate in
compound 3.6. The creation of an orthoquinone methide accounts for the loss of m/z =
106 observed in the mass spectrum.

This mechanism describes the creation of an orthoquinone methide. This explains
the loss of the appropriate mass as well as the maintenance of the uncharged nature of the
N-terminal chelate required for agreement with the observed fragmentation.

The

resultant bidentate chelate contains an amide functionality which balances the overall
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positive oxidation state of the rhenium(I) tricarbonyl. There are four relatively intense
fragments that correspond to the loss of a quinone methide (Table 3.5).
Table 3.5 The observed fragments in the product ion spectrum of compound 3.6 due to
the loss of an m/z = 106 corresponding to the loss of an orthoquinone methide.
Series and
Label
[M+H]+ - 106
b8 - 106
b1 - 106
a1 - 106

Fragment
Re(CO)3-PHA-QATDKFTF-NH3+ - 106
Re(CO)3-PHA-QATDKFTF - 106
Re(CO)3-PHA-Q – 106
Re(CO)3-PHA-Q – 106

Observed m/z
1374.5
1357.5
547.1
519.1

From the fragmentation results of the PHA chelate organometallic peptide, it is
clear that rhenium(I) tricarbonyl chelates are not universally stable to the fragmentation
conditions. The additional information obtained from these experiments is important if a
MALDI TOF/TOF sequencing method is to be used in the screening of organometallic
OBOC libraries.

3.3 Conclusions

The results of these experiments into the fragmentation patterns of rhenium(I)
tricarbonyl peptides has provided useful information into the effects of N-terminal
organometallics on peptide fragmentation. These results have provided the first de novo
sequencing of rhenium(I) tricarbonyl containing peptides which provides a foundation for
further research into the identification of organometallic peptides for use in molecular
imaging.

78

The same peptide sequence was used with the addition of four rhenium(I)
tricarbonyl bifunctional chelates that have been directly attached to the peptide Nterminus. All of the resulting compounds were successfully sequenced by tandem mass
spectrometric methods. The fragmentation patterns of neutral, positive and negative
organometallics provide an insight into the different effects of the N-terminal chelates.
The fragmentation patterns are unique between each charge state, most likely the result of
different three dimensional conformations and mobile proton pathways during collisioninduced dissociation. Furthermore, PADA and PHA, both neutral chelates, also produce
different fragmentation patterns. The steric differences between a carboxylate and phenol
ring produce unique fragmentation patterns and especially relative intensities between
peaks.
Overall, the rhenium(I) tricarbonyl chelates have proven to be extremely stable to
decarbonylation in MALDI mass spectrometry, in opposition to the literature reports.
The chelates, in general, have also been shown to be stable to fragmentation conditions,
with the notable exception of 3.6, producing spectra that can be interpreted to fully
sequence peptides. The results of these experiments have shown that MALDI TOF/TOF
is an appropriate method for deconvolution of organometallic OBOC libraries.

3.4 Experimental
3.4.1 General procedures and materials

All chemicals and solvents were purchased from commercially available sources
and used without further purification. Coupling agents, resin and Fmoc amino acids were
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purchased from Peptides International (Louisville, KY) or Aapptec (Louisville, KY).
Solvents and other chemicals were purchased from Fisher Scientific and Sigma Aldrich.
Analytical HPLC was preformed utilizing a Waters Sunfire C18 column 4.6 x 150 mm, 5
µm. Semi-preparative HPLC was preformed utilizing a Waters Sunfire Prep C18 OBD
column 19 x 150 mm, 5 µm or a Waters Atlantis T3 Prep C18 OBD column, 19 x 150
mm, 5 µm. The gradient system utilized consists of acetonitrile + 0.1% TFA (Solvent A)
and water + 0.1% TFA (Solvent B). Ultraviolet absorbance measurements were obtained
utilizing a Waters 2998 Photodiode Array Detector and Mass spectra were obtained via
electrospray ionization utilizing a Micromass Quatro Micro LCT mass spectrometer.
MALDI mass spectrometry experiments were done utilizing an Applied Biosystems 4700
PDS. This instrument is equipped with an Nd: YAG laser tuned to a wavelength of 355
nm, with a 200 Hz laser rate operating in reflectron mode and tandem time-of-flight ion
detectors in series. The mass spectrometer was calibrated with a mixture of angiotensin I
(m/z 1296.685), Glu-1-Fibrino-peptide B (m/z 1570.677) to a mass accuracy of ± 0.5 Da.

3.4.2 General Peptide Synthesis

Standard Fmoc solid phase peptide synthesis was performed in order to obtain the
desired peptide with side chain protecting groups. Rink amide MHBA NH2 resin ( 0.1
mmol, 0.28 meq/g) containing an Fmoc protecting group was utilized. The resin was
swelled with DMF and DCM washes. The Fmoc was removed with a solution 20%
piperidine in DMF (2x, 5 min and 20 min, respectively). The residual deprotection
solution was removed from resin using DMF and DCM washes. Fmoc-protected amino
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acids (0.3 mmol, 3 eq) were dissolved in DMF (0.5 mL) along with HBTU or HCTU (0.3
mmol, 3 eq) and DIPEA (0.6 mmol, 6 eq). The amino acids used were Fmoc-Phe-OH,
Fmoc-Thr(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Ala-OH and
Fmoc-Gln(Trt)-OH. The solution was then combined with the resin and agitated for one
hour. The resin was then washed with DMF and DCM. This process was repeated as
second time for one and a half hours. This deprotection/coupling process was repeated
for each amino acid. Chelates were added using similar procedures.

3.4.3 Organometallic Coupling Procedure

Compounds 3.2, 3.3, 3.4
The chelate (0.4 mmol, 4 eq.) was dissolved in DMF (2 mL/1 mL for PADA (2.7)/BPA
(2.9) and NTA (2.10), respectively) with HBTU or HCTU (0.4 mmol, 4 eq.) and DIPEA
(0.8 mmol, 8 eq.) and mixed with peptide containing Rink Amide resin (0.1 mmol). The
resin and solution were agitated overnight and subsequently washed with DMF and DCM
resulting in the desired organometallic peptide.
Compound 3.6
The Rink Amide resin (0.1 mmol) and 2.13, the PHA chelator (0.4 mmol, 4 eq.) in 2 mL
of DMF with HCTU (0.4 mmol, 4 eq.) and DIPEA (0.8 mmol, 8 eq.) and mixed
overnight. The resin was washed with DMF and DCM resulting in compound 3.5. Then,
[Et4N]2[Re(CO)3Br3] (0.2 mmol, 2 eq.) in 1 ml of a 50:50 mixture of MeOH/DMF (v/v)
with DIPEA (0.2 mmol, 2 eq.) is added to the resin containing compound 3.5. The resin
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and solution was mixed overnight. The resin was then washed with DMF and DCM
resulting in compound 3.6.

3.4.4 Peptide Deprotection, Cleavage and Purification

The organometallic peptides on resin were mixed with a solution of 95% TFA,
2.5% H2O and 2.5% TIS (1 mL) for three hours to remove the peptide from resin as well
as remove side-chain protecting groups. The resulting solution was cooled on ice and
cold tert-butyl methyl ether (TBME) (1 mL) was added dropwise to the solution until a
white precipitate formed. The solution was then centrifuged at 0oC at 3000 rpm for 10
minutes. The liquid was decanted and the resulting pellet was mixed with cold TBME (1
mL) and subsequently centrifuged again under identical conditions to obtain the crude
peptide.
The crude peptides were dissolved in water and purified by HPLC and identified
by mass spectrometry, resulting in white powders.
Re(CO)3-PADA-QATDKFTF-NH2 (3.2)
The compound was synthesized via standard solid phase peptide synthesis techniques and
purified by preparative HPLC (15 min linear gradient 30% solvent A in solvent B to
70%). The purity and identity of the compound was assessed by analytical HPLC and
mass spectrometry, respectively. Purity: 98%. MS (MALDI) [M+H]+ m/z calc: 1432.5
obs: 1432.5. (Rhenium-187)
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Re(CO)3-BPA-QATDKFTF-NH2 (3.3)
The compound was synthesized via standard solid phase peptide synthesis techniques and
purified by preparative HPLC (15 min linear gradient 20% solvent A in solvent B to
90%). The purity and identity of the compound was assessed by analytical HPLC and
mass spectrometry, respectively. Purity: 93%. MS (MALDI) [M]+ m/z calc: 1465.5 obs:
1465.6. (Rhenium-187)
Re(CO)3-NTA-QATDKFTF-NH2 (3.4)
The compound was synthesized via standard solid phase peptide synthesis techniques and
purified by preparative HPLC with a gradient (15 min linear gradient 20% solvent A in
solvent B to 90%). The purity and identity of the compound was assessed by analytical
HPLC and mass spectrometry, respectively. Purity: 90%. MS (MALDI) [M+2H]+ m/z
calc: 1399.5 obs: 1399.5. (Rhenium-187)
Re(CO)3-PHA-QATDKFTF-NH2 (3.6)
The compound was synthesized via standard solid phase peptide synthesis techniques and
purified by preparative HPLC with a gradient (15 min linear gradient 25% solvent A in
solvent B to 80%). The purity and identity of the compound was assessed by analytical
HPLC and mass spectrometry, respectively. Purity: 95%. MS (MALDI) [M+H]+ m/z
calc: 1480.5 obs: 1480.5. (Rhenium-187)
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3.4.5 MALDI Tandem Mass Spectrometry

Purified organometallic peptides were dissolved in water at a concentration of
approximately 0.02 g/mL. A portion of the organometallic peptide solution (2 µL) and a
CHCA solution (2 µL) were mixed for a few minutes. CHCA solution is a mixture of
50:50 water/acetonitrile with the addition of 0.1% TFA (v/v) at a concentration of 5
mg/mL. A portion of the mixture (0.7 µL) was then spotted onto a MALDI plate in
duplicate for analysis. The solvent in the mixture was allowed for evaporate resulting in
the co-crystallization of the matrix and peptide. The samples were then analysed via
MALDI tandem mass spectrometry. The precursor ion spectra show rhenium-185/187
isotopic distributions. The rhenium-185 peak was chosen for fragmentation via collision
induced dissociation with argon gas. Tandem mass spectra were obtained and peaks
assigned via manual de novo peptide analysis.
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Chapter 4: The Synthesis and Screening of Organometallic OBOC
Peptide Libraries
4.1 Introduction
4.1.1 OBOC Libraries

OBOC libraries can be used to screen for bioactive molecules against particular
receptors, enzymes or other targets.

In the previous chapter, MALDI tandem mass

spectrometry has been shown to provide a useful and efficient method to determine the
amino acid sequences of organometallic peptides. Mass spectrometry can then be applied
to the sequencing of organometallic OBOC peptide libraries. These libraries have the
potential to be a powerful tool in developing targeted peptide-based imaging agents.
Traditionally, OBOC libraries have not been popular in developing imaging
agents for a number of reasons. OBOC libraries contain a large number of beads, each
single bead contains many copies of the exact same compound. Peptides are thought to
sometimes be present in unusual conformations in OBOC libraries due to the high
concentration of peptide on a single bead.94

Also, the presence of the polystyrene

backbone of the bead can also have a large effect on the conformations of peptides.
Therefore, bioactive peptide hits need to be re-evaluated in solution after the library has
been screened. Furthermore, due to the unnaturally high concentration of peptide on
library beads, false positive hits also can be a problem because of interactions between
peptides and the many macromolecules present on cell surfaces. In addition, the initial
formulation of an OBOC screening method was heavily reliant on manual separation of
beads for analysis.95

This process was inherently slow and low-throughput, further

discouraging its use. However, with the application of fluorescence sorting and the
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development of high-throughput mass spectrometry these problems can largely be
overcome in order to screen libraries efficiently and economically.
The main advantage to utilizing OBOC libraries is the ability to create a large
diverse library in which many compounds can be tested against targets. Moreover,
OBOC libraries are built through chemical synthesis, and as such, can include a large
variety of chemical scaffolds. Aside from naturally occurring amino acids, there are a
wide variety of unnatural amino acids, D-amino acids, linkers and non-peptide
components available. Natural peptides, in general, have short biological half-lives, and
the addition or replacement of natural amino acids with non-natural mimics increases
their stability. Because OBOC peptide libraries can include these non-natural mimics, it
is a very appealing method for developing peptide-based imaging agents. Recently, there
has been an interest in furthering the use of OBOC libraries in developing non-peptide or
unnatural libraries.
Aditya et al. recently reported the synthesis and sequencing, through MALDI
MS/MS, of an OBOC library containing peptide-like compounds with unnatural
heterocycle side-chains (N-substituted oligo-glycines)96 (Figure 4.1). These types of
compounds are promising for therapeutic and diagnostic applications because they have
similar properties to peptides; however they are resistant to biological degradation. The
chemistry associated with synthesizing these compounds on the solid-phase is not fully
developed and results in incomplete and impure libraries
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Figure 4.1 An example of the peptide-like compounds created in OBOC libraries by
Aditya et al. These compounds are similar to peptides in structure, however they are
expected to have long biological half-lives. These compounds were sequencing by
MALDI TOF/TOF.

Another recent example of utilizing unnatural compounds has been shown by
Goksel et al. in developing drugs against the androgen receptor. An OBOC peptide
library containing unnatural amino acids was synthesized and tested for binding affinity.
This resulted in a number of “hit” sequences deconvoluted through MALDI TOF ladder
peptide

synthesis.

The

best

hit

resulted

in

the

peptide

sequence

SSRXESXXAGEKESRG, where X are β-(2-naphthyl)alanine, β-cyclohexylalanine and
tryptophan, and the binding affinity measured is 0.47 µM.97
Recently, Bachor et al. have developed OBOC peptide libraries containing Nterminal quaternary ammonium salts. Peptides were reacted with iodoalkanes to form
positively charged N-terminal residues.

The purpose of these positively charged

ammonium N-terminal residues is to provide increased sensitivity to mass spectrometric
analysis of peptides,98 and has resulted in the successful sequencing of these modified
peptides. This methodology bears similarities to the development of organometallic
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OBOC peptide libraries with rhenium(I) tricarbonyl chelates on the N-terminus of the
peptide sequence.
Despite the increased use of OBOC libraries to develop peptide or peptide-like
compounds, developing imaging agents via this method has been generally neglected due
to the necessary modifications after screening. The proposed solution to this problem is
to develop organometallic OBOC peptide libraries that take into account the effects of the
imaging entity on the binding affinity of a peptide sequence.

4.1.2 Glucagon-Like Peptide 1 Receptor

The GLP-1R (glucagon-like peptide 1 receptor) is a promising target for
developing imaging agents. The receptor is a member of GPCR (G Protein-Coupled
Receptor) superfamily. This class of receptors is currently one of the most important
drug targets in modern medicine as roughly half of all pharmaceuticals target this
superfamily of receptors. The endogenous ligand of GLP-1R, glucagon-like peptide 1
(GLP-1), is a peptide hormone produced in the body which has roles in regulating blood
glucose in response to nutrient digestion.99 GLP-1, in its bioactive form, is a peptide
containing 29 amino acids which is produced in intestinal L-cells. GLP-1 receptors are
found largely in pancreatic beta cells which are responsible for insulin secretion.
Because of this, the GLP-1R is an important target for treatment of type II diabetes.
Furthermore, GLP-1R is also an important potential target for imaging of various
insulinomas. These cancers often over-express the GLP-1R and a targeting imaging
agent would be a very useful for diagnosis and monitoring.
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Glucagon-like peptide 1 is produced through modification of the peptide
prohormone proglucagon.100 The products of the processing reactions result in a number
of bioactive compounds, such as GLP-2 and glucagon, in addition to GLP-1 which
usually exists as GLP-1(7-36) with a C-terminal amide.

The binding interactions

between GLP-1 and its corresponding receptor have been determined through alanine
scans101 and side-chain modifications102 to identify the necessary amino acids for binding
and the potential for imaging entity addition along the backbone, respectively. In
addition, there have been reports of crystal structure determinations of the GLP-1R Nterminal extracellular domain with peptide antagonists at a resolution of 2.2 Å103 and
more recently 2.1 Å104 to investigate peptide-receptor interactions. From these results, it
can be shown the GLP-1R has two distinct binding motifs that GLP-1(7-36) amide
interacts with simultaneously, with a binding affinity of approximately 0.16 nM.105 This
results in a large number of amino acids of GLP-1 being necessary for binding affinity to
be maintained. The alanine scans, side chain modification studies and crystal structures
have shown that not only are a large number of GLP-1(7-36) amino acids necessary for
maintenance of binding affinity, these amino acids are also located along the entire length
of the backbone; therefore, modifications are non-trivial exercises.
GLP-1, like most naturally occurring peptides, has been shown to have a short
biological half-life of approximately two minutes. The poor biological stability of GLP1(7-36) is due to the presence of L-alanine in position 8, which is susceptible to cleavage
by the enzyme dipeptidyl peptidase-IV.106 The replacement of the L-alanine with Dalanine or aminobutyric acid increases the stability of the peptide significantly, allowing
GLP-1(7-36)amide to be a promising therapeutic and diagnostic pharmaceutical.

A

89

number of GLP-1 analogues have or are currently undergoing clinical trials for treatment
of diabetes, such as Victoza, which possesses a 97% sequence identity to GLP-1 with the
addition of a fatty acid to the side chain of one amino acid.107 In addition to GLP-1,
exendin has also been shown to be a high affinity ligand of the GLP-1R. The exendin
peptide hormone was isolated from the saliva of the lizard Heloderma suspectum in
1992.108 The peptide possesses a 53% sequence identity to GLP-1,109 has a significantly
longer biological half-life and shows higher binding affinity to the GLP-1R. Currently,
the peptide is used for treatment of diabetes through injections under the brand name
Exenatide.
Despite the moderate success of GLP-1 and exendin analogues as therapeutic
pharmaceuticals for treatment of diabetes, imaging agents have yet to be fully developed
based on these peptide sequences.

Initially, iodine-123 conjugates of GLP-1 and

exendin-3 were developed as SPECT agents for detection of insulinomas. The results of
these studies indicated that the accumulation of the molecular probe in the tumor was
poor, suggesting that the iodine conjugates were not stable to biological conditions.
Modification of the exendin-3 peptide at the lysine in the forty position with gallium-68
and indium-111 chelates led to the creation of [Lys40(68Ga-DOTA)]-exendin-3 and
[Lys40(111In-DTPA)]-exendin-3. These imaging agents have shown selective uptake in
subcutaneously insulinoma tumors implanted in mice.110

However, there is also

significant uptake in the kidneys most likely due to the positive charges present on lysine
and arginine side chains. Furthermore, recent in vitro studies of a GLP-1 derivative with
an AEEA (2-aminoethoxy-2-ethoxy acetic acid) linker, [Lys37AEEA(111In-DOTA)]GLP-
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1 show high binding affinity to the GLP-1R.111 However, similar problems with in vivo
distribution of the imaging agent are observed.
Despite the development of promising imaging agents with high binding affinity
to the GLP-1R developed based on the scaffolds of GLP-1 and exendin, there are
problems associated with the biodistribution and specificity of the imaging agents. GLP1 and exendin represent some common pharmacokinetic problems associated with using
large peptides as targeting entities. Therefore, it is beneficial to develop a new class of
peptide-based imaging agents for the GLP-1R that are not based on the structure of the
endogenous ligands and have a significantly reduced size.

The development of

organometallic OBOC peptide libraries provides a potential method to overcome the
limitations associated with endogenous ligand scaffolds in discovering small peptide
molecules with high affinity.
The nature of the active site of the GLP-1R requires interactions between the
ligand and the receptor at a variety of spatially distant points. This results in the GLP-1
having a large number of amino acids that are considered necessary for binding and that
are located through the entire backbone of the peptide hormone. As such, it is unlikely
that small peptide-based imaging agents will interact with the active site. Therefore, the
library screening of small peptides might result in allosteric interactions between the
ligand and the target. Family B of the GPCR superfamily, of which GLP-1R is a part,
has been shown to be resistant to the development of compounds showing allosteric
interactions.112 There are few reports of compounds showing allosteric interactions with
the GLP-1R, all of which are small molecules (Figure 4.2)
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Figure 4.2 Allosteric small molecule antagonists of the GLP-1R.

The first molecule, T-0632, discovered to allosterically block peptide activity at
the GLP-1R was reported in 2001.113 The compound has an observed IC50 = 1.2 µm ±
0.4 µm. 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylamino quinoxaline and Quecetin
were investigated in 2010,114 the former was previously found to be an allosteric
modulator with a binding affinity of 0.1 µm ± 0.2 µm.115 Their binding properties were
investigated and found that they interact differently with the GLP-1R as they do not
produce the same effects on cell pathways such as cAMP signal pathway stimulation and
intracellular Ca2+ levels.
The binding interactions of these small molecule inhibitors are not well
understood as the binding mechanism and binding site are not known. Nevertheless,
these few compounds demonstrate the ability to discover compounds which can interact
with GLP-1R in an allosteric fashion. Fortunately, knowledge of allosteric binding
interactions is not a prerequisite to developing allosteric-based imaging agents. As long
as a potential imaging agent binds to the GLP-1R with high binding affinity and
specificity, the particular binding interactions do not necessarily need to be fully
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understood, because imaging agents are introduced to the body in small quantities in
comparison to therapeutic pharmaceuticals. Therefore, the affect of the binding of the
imaging agent on the signalling pathway cascades are negligible.
The development of allosteric GLP-1R imaging agents provides means to
overcome the difficulty of utilizing the scaffolds of GLP-1 and exendin. These large
peptides have poor pharmacokinetic properties; comparatively, small peptides, do not
have these problems, in general. Because of the properties of the GLP-1R binding site,
small peptides would be expected to interact through allosteric means. Therefore, the use
of organometallic OBOC peptide libraries can be utilized to discover small peptides that
interact with the GLP-1R.

4.2 Results and Discussion
4.2.1 Single bead MALDI Tandem Mass Spectrometry

The use of tandem time-of-flight mass spectrometry to sequence rhenium(I)
tricarbonyl-containing peptides that were previously synthesized and purified in bulk
quantities, has been shown to be an effective method for amino acid determination.
However, these conditions are not indicative of the methods used in OBOC screening.
Different resin, different cleavage techniques, lower quantities and lack of purification
are all conditions of OBOC library screening that need to be addressed. Therefore, the
first step in creating an organometallic OBOC peptide library is to verify the ability to
sequence OBOC beads under library screening conditions.
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The use of tentagel S NH2 resin is necessary for OBOC peptide libraries. The
difference between Rink Amide and tentagel resin is based on the functional groups to
which the peptides are attached. Tentagel contains a free amine, and as such forms an
amide bond when peptides are attached. Therefore, the acidic cleavage conditions which
remove side-chain protecting groups, do not remove the peptide from the resin. This is
important because the peptides need to be deprotected but still remain on the resin in
order to be screened against GLP-1R. Then, in order to sequence the peptide through
MALDI MS/MS, the peptide needs to be cleaved through the use of an ANP (2-amino-3(2-nitrophenyl)propanoic acid) photolinker (Scheme 4.1).

Scheme 4.1 The synthesis of compound 3.2 on tentagel S NH2 resin with a UV cleavable
ANP photolinker. The organometallic peptide was cleaved from a single bead.
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First the Fmoc-ANP photolinker was added to the resin under standard coupling
conditions, and subsequently deprotected. In the absence of light, Fmoc-amino acids
were added sequentially resulting in the peptide H-QATDKFTF. The organometallic was
added under standard conditions. TFA/scavengers are then used to deprotect the sidechains of the amino acids with the peptide remaining on the resin. This was verified by
the lack of observable peptide in the TFA/scavengers solution after three hours of sidechain cleavage.

Subsequently, under a fluorescence microscope, a single bead was

selected and placed in approximately 50 µL of water and cleaved through the use of UV
light for three hours, resulting in a dilute solution of organometallic peptide. These
conditions are identical to the conditions that an OBOC library would be screened. This
produces a solution of compound 3.2 that is mixed with a CHCA solution and MALDI
tandem mass spectrometry is then used to sequence the peptide. The resultant tandem
mass spectrum is compared to the bulk-purified peptide results (Figure 4.3)
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Figure 4.3 A comparison of the product ion spectra of compound 3.2 obtained by
MALDI TOF/TOF mass spectrometry. a) The spectrum of the HPLC purified
organometallic peptide. b) The spectrum of the organometallic peptide cleaved from a
single 90 µm tentagel bead under OBOC screening conditions. The spectra are very
similar and contain identical peaks.
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The product ion mass spectrum obtained is almost identical to the purified peptide
spectrum. All of the same peaks are present in the single-bead spectrum and the HPLC
purified spectrum. This provides good evidence for the applicability of MALDI tandem
mass spectrometry to organometallic OBOC peptide library screening.

4.2.2 Organometallic OBOC Peptide Library Synthesis

Because of the success of sequencing an organometallic peptide from a single
tentagel bead with an ANP linker, a library of Re(CO)3-PADA organometallic peptides
was created to be screened against the GLP-1R. All natural amino acids were used,
except cysteine, methionine and isoleucine. Cysteine forms disulfide bonds between
peptide chains that would result in difficulty in sequencing procedures. Methionine is not
stable to UV cleavage conditions and is prone to oxidation. Isoleucine is isobaric with
leucine and they cannot be distinguished from each other by mass spectrometry.
Therefore, seventeen amino acids are used to create peptides with eight amino acids.
This results in a library of almost seven billion (178) possible peptide sequences.
However, in order to create a library with that many peptide sequences, kilograms of
resin would be required; this is neither economical nor practical. Only 1 g of beads is
used in the library resulting in approximately 1.5 million unique peptide sequences.
Beads are coupled to Fmoc-ANP-OH and subsequently separated into 17 different
wells, each corresponding to a different amino acid.

Using an automatic peptide

synthesizer, each bead is deprotected and a unique peptide is added to each well. The
beads from each well are then recombined, mixed together, and then split back into the
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wells. This iterative cycle is repeated eight times until a library of beads, each with a
unique peptide sequence, was created. Initially, utilizing three equivalents of amino acid,
the peptide coupling was observed to be incomplete, resulting in the observation of
multiple different peptides present on a single bead. Increasing the proportion of amino
acids to five equivalents, as well as the coupling time, resulted in complete coupling as
observed by mass spectrometry. The beads are then recombined and then the Re(CO)3PADA complex is added to the N-terminus of the peptide. Four equivalents of the
rhenium(I) tricarbonyl complex are coupled per peptide chain, resulting in complete
conversion. Five millilitres of a mixture of TFA/H2O/TIS was added to the beads in
order to remove the side-chain protecting groups of the amino acids. The purity of the
library is accessed through MALDI mass spectrometry, in which only one compound is
observed for each single bead. The resultant beads contain a unique organometallic
peptide connected to the bead through an ANP photolinker. The organometallic peptide
contains no protecting groups and can be screened against the GLP-1R target.

4.2.3 Single Bead Organometallic OBOC Peptide Deconvolution

Single beads from the library were selected from the library in order to determine
the ability of MALDI MS/MS to sequence unknown organometallic octapeptides.
Previously, rhenium(I) tricarbonyl peptide sequences have been sequenced through this
method, however the identity of the peptide is already known. The de novo sequencing
of unknown organometallic peptides is significantly more difficult in comparison because
peaks cannot be expected to be present. As such, single beads from the library were
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individually selected via the use of a fluorescence microscope.

Then, beads were

irradiated with UV light for three hours in approximately 50 µL of water. The resultant
organometallic peptide sequences were co-crystallized with CHCA and MALDI tandem
spectra were obtained and sequenced (Table 4.1).
Table 4.1 Deconvoluted PADA-Re(CO)3 peptides from an organometallic OBOC
peptide library sequenced through manual de novo methods.
Compound
4.1
4.2
4.3
4.4
4.5
4.6
4.7

Deconvoluted Organometallic Peptide
Sequence
[PADA-Re(CO)3]-VLYGVRPV-NH2
[PADA-Re(CO)3]-ALHEVGSW-NH2
[PADA-Re(CO)3]-HNES(K/Q)EGT-NH2
[PADA-Re(CO)3]-FEGGEESY-NH2
[PADA-Re(CO)3]-YARES(K/Q)AD-NH2
[PADA-Re(CO)3]-DHHLRAYV-NH2
[PADA-Re(CO)3]-TEHNP(K/Q)HE-NH2

Calculated Observed
Mass (m/z) Mass (m/z)
1335.51
1335.49
1373.46
1373.43
1376.38
1376.43
1392.40
1392.37
1414.47
1414.45
1443.48
1443.46
1466.44
1466.48

The observed organometallic peptides all contain eight amino acids, consistent
with the library properties. The ability to sequence these peptides was aided by the
rhenium isotopic signature present on N-terminal fragments, allowing the ability to
distinguish between N and C-terminal fragments. Furthermore, the mass of the Re(CO)3PADA chelate is known and facilitates the sequencing by starting de novo sequencing at
a universal m/z value. In addition, from the precursor spectrum, the total mass was also
known. The resultant table of peptides shows calculated and observed mass in close
agreement (Table 4.1). Lysine and glutamine are almost isobaric and therefore cannot be
distinguished in mass spectrometry. Like Re(CO)3-PADA-QATDKFTF-NH2, (3.2), the
most intense peak in almost all of the deconvoluted organometallic peptide sequences,
with the exception of 4.5, was the b1 fragment, suggesting that this fragmentation pattern
is in general the most favourable pathway for N-terminal PADA rhenium(I) tricarbonyl
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chelates.

Approximately 50% of beads sequenced by MALDI MS/MS resulted in

complete assignments of amino acids. Many of the incomplete fragmentation patterns
resulted in the majority of amino acids being assigned, with the omission of two amino
acid identities. Despite the fact that not all of the peptide sequences could be identified, a
fifty percent success rate is acceptable because the purpose of screening is to identify
bioactive peptides and not to infer about structure-activity relationships.

4.2.4 Organometallic OBOC Peptide Library Screening Against the GLP-1R

In order to find bioactive peptide sequences that target the GLP-1R from the
organometallic OBOC peptide library, fluorescent CHO (Chinese hamster ovarian) cells
over-expressing the GLP-1R were created. These cells were then incubated with the
OBOC library and the beads containing the bioactive organometallic peptide sequences
had cells attached to them.

In order to facilitate high throughput screening, after

incubation, the beads are sorted utilizing a COPAS biosorter. The biosorter flows beads
and lasers are used to measure the fluorescence, the size of the particle and the extinction
(the amount of light which is blocked by the particle). The beads that have cells bound to
them have a larger size and higher fluorescence. In this way, beads that have bioactive
peptides can be separated from beads which do not have bioactive peptides due to the
lack of peptide-cell interaction on the latter.
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Figure 4.4 The procedure for screen an OBOC peptide library against cells. This
technique accounts for non-specific binding interactions.

The process of screening an organometallic OBOC peptide library against the
GLP-1R begins with the incubation of the library with CHO cells expressing the GFP
(green fluorescent protein). These cells are green fluorescent and are used as a control to
account for non-specific binding in the peptide library. Peptide sequences would be
expected to interact with some of the thousands of biomolecules expressed on a cells’
surface, and as such if the organometallic peptide sequences interact with these
biomolecules they produce false positive results (Figure 4.5).
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Figure 4.5 Organometallic OBOC peptide library after incubation with GFP expressing
cells. There are a number of beads circled in white that show interaction with the cells
while most do not. The intensity of the auto-fluorescence of the tentagel beads varies
from bead to bead.

In order to account for these interactions, the incubation of the organometallic
OBOC peptide library with CHO cells allows for the removal of the peptides showing
these interactions. The beads that did not show interaction with the control green CHO
cells were then incubated with red GLP-1R over-expressing CHO cells.
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Figure 4.6 A diagram of CHO cells showing green and red fluorescence. The green
cells express GFP (green fluorescent protein) and act a control for non-specific binding.
The red cells express tdTomato and overexpress the GLP-1R.

The organometallic OBOC peptide library (1.5 million beads) was incubated with
approximately 10 million CHO control cells suspended in 10 mL of PBS for one hour
being mixed at 300 rpm at 37 oC. After incubation, formaldehyde was added to the
solution in order to attach the cells to the beads permanently. The formaldehyde reacts
with the biomolecules present on cell surface in order to create cross-linking. The beads
were then rinsed with PBS three times in order to remove any of the unbound cells. The
beads were then sorted via the COPAS biosorter.

From the results, two distinct

populations of the beads are shown in the library, the more fluorescent population contain
control cells bound to the beads (Figure 4.7).
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Figure 4.7 A graph from the COPAS biosorter showing two distinct populations of
beads after incubation with green control cells. The y-axis is a measurement of green
fluorescence and the x-axis is the time-of-flight or size. The top population shows
increased fluorescence and contains GFP CHO cells with non-specific binding
interactions. The bottom population contains no cells.

The population containing smaller, less fluorescent beads have not interacted with
cells. After isolating these populations, investigation of the beads under a fluorescent
microscope revealed that most of the bottom population have no cells bound to them and
most of the more fluorescent population contain cell-bead interactions (Figure 4.8).
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Figure 4.8 Tentagel bead interacting with three visible GFP expressing cells.

After the non-interacting bead population was isolated, the beads were incubated
with red GLP-1R over-expressing cells utilizing the same procedure as outlined above.
The biosorter was once again used to separate two populations of beads, those showing
and not showing interactions with the GLP-1R.

In this case, the beads showing

interactions with the cells were to be isolated to find peptide sequences interacting with
the GLP-1R. However, there were problems associated with bead sorting based on red
fluorescence on the COPAS biosorter that could not be overcome to produce conditions
to find two separate populations. The auto-fluorescence of the beads in the red is not as
uniform as it is in green, and the variation in red fluorescence masks the bioactive beads.
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Figure 4.9 A graph from the COPAS biosorter with the y-axis is a measurement of red
fluorescence and the x-axis is time-of-flight or size. This graph illustrates that there are
not two distinct populations of beads containing red cells and those without.

Therefore, because of the difficulties associated with screening red fluorescence,
manual separation under a fluorescence microscope was utilized.

The beads were

isolated from each other via the identification of red cells bound to beads and picking the
beads out with a pipette. This process is time consuming, technically challenging and not
inherently high throughput. Approximately 20 beads were isolated via this method. The
organometallic peptides were cleaved from resin utilizing a UV light for three hours and
MALDI was subsequently preformed on the resultant solution.

4.2.5 MALDI TOF/TOF Deconvolution of “Hit” Library Beads

The MALDI tandem mass spectrometry results of the 20 beads produced mass
spectra with minimal signals. Most of the beads showed no signal in the corresponding
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mass spectrum. It is suspected that the time-consuming isolation of beads under the
fluorescent microscope resulted in the cleavage of much of the organometallic peptides
from the resin. Light is shone on the beads in order to induce fluorescence, the ANP
photolinker was cleaved and peptide removed from resin. Unfortunately, out of the 20
isolated beads, only two produce a precursor ion spectrum. Of these two peptide hits,
only one of their corresponding product ion spectra could be fully deconvoluted via de
novo sequencing.

The organometallic peptide was identified as Re(CO)3-PADA-

RVTH(K/Q)(K/Q)(K/Q)E-NH2 (4.8) through the use of b ion fragments (Figure 4.10).

Figure 4.10 The product ion spectrum of the organometallic octapeptide 4.8 showing the
b series fragments.

The product ion spectrum of compound 4.8 shows similar properties to the
previously investigated Re(CO)3-PADA organometallic peptides. The b1 fragment is by

107

far the most intense, as was the case with every previous Re(CO)3-PADA peptide except
for compound 4.5. The compound contains three positions which have been assigned
either lysine or glutamine. As such, the actual identity of the peptide is one of eight
possible peptides.
Table 4.2 Fragment assignments from series b of the product ion spectrum of compound
4.8. The masses of the b8 ion can be determined because of the known mass of the
peptide and the N-terminal chelate. [M+H]+ m/z = 1497.52 (rhenium-185 peak).
Label

b0
b1
b2
b3
b4
b5
b6
b7
b8

Fragment

RE-PADA-NH3
RE-PADA-R
RE-PADA-RV
RE-PADA-RVT
RE-PADA-RVTH
RE-PADA-RVTH(K/Q)
RE-PADA-RVTH(K/Q)(K/Q)
RE-PADARVTH(K/Q)(K/Q)(K/Q)
NOT OBSERVED

Peak
(m/z)

Difference
between
peaks
(m/z)

Amino Acid
Assignment

492.0
631.1
730.2
831.3
968.3
1096.4
1224.4

156.1
Arginine
99.1
Valine
101.1
Threonine
137.1
Histidine
128.1 Lysine/Glutamine
128.0 Lysine/Glutamine

1352.5
1481.5

128.1 Lysine/Glutamine
129.0
Glutamic Acid

The other peptide “hit” was partially sequenced via de novo methods.
identity of the peptide sequence is Re(CO)3-PADA-SWGxxLFS-NH2 (4.9).

The

The b1

fragment is again the most intense peak in the spectrum (Figure 4.11). Two positions
could not be identified due to lack of fragmentation at that position.
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Figure 4.11 The product ion spectrum of the organometallic octapeptide 4.9 showing the
b series fragments.

The mass allotted to the unknown dipeptide (xx) is approximately m/z 184. Based
on the known masses of amino acids, the identity of these two amino acids could be
either a combination of proline and serine or alanine and leucine. Additionally, the order
of the two amino acids is not known. This highlights the limitations associated with de
novo sequencing. Despite the fact that eight of nine b series fragments were determined,
the identity of the peptide sequence could only be narrowed down to four potential
sequences.
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Table 4.3 Fragment assignments from series b and y of the product ion spectrum of
compound 4.9. The masses of the b8 ion can be determined because of the known mass
of the peptide and the N-terminal chelate. [M+H]+ m/z = 1353.48 (rhenium-185 peak).
Series

b
series

Label

b0
b1
b2
b3
b4
b5
b6
b7
b8

Fragment

NOT OBSERVED
RE-PADA-S
RE-PADA-SW
RE-PADA-SWG
RE-PADA-SWGx
RE-PADA-SWGxx
RE-PADA-SWGxxL
RE-PADA-SWGxxLF
NOT OBSERVED

Peak
(m/z)

Difference
between
peaks
(m/z)

Amino Acid
Assignment

475.0
562.0
748.1
805.1

87.0
186.1
57.0

Serine
Tryptophan
Glycine

989.3
1102.3
1249.4
1336.4

113.1
147.1
87.0

Leucine
Phenylalanine
Serine

From the information given by the two organometallic peptide sequences, the two
sequences do not appear to be similar. Compound 4.8 is a very positively charged
peptide species, containing an arginine, histidine and potentially as many as three lysine
residues, all of which are capable of holding a positive charge. Conversely, 4.9 is a
largely hydrophobic peptide sequence containing phenylalanine, leucine, glycine and
tryptophan with hydroxyl group of serine being the only polar functionality within the
organometallic peptide. Therefore, it is difficult to draw any conclusions about the
binding properties of organometallic octapeptides. In order to determine patterns among
this class of bioactive molecule a larger sample of peptide “hit” sequences is necessary.
Furthermore, compounds 4.8 and 4.9 need to be evaluated in solution phase in order to
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determine their quantitative binding affinities in order to determine their true ability to
interact with GLP-1R.
From the information given by the two organometallic peptide sequences, the two
sequences do not appear to be similar. Compound 4.8 is a very positively charged
peptide species, containing an arginine, histidine and potentially as many as three lysine
residues, all of which are capable of holding a positive charge. Conversely, 4.9 is a
largely hydrophobic peptide sequence containing phenylalanine, leucine, glycine and
tryptophan with hydroxyl group of serine being the only polar functionality within the
organometallic peptide. Therefore, it is difficult to draw any conclusions about the
binding properties of organometallic octapeptides. In order to determine patterns among
this class of bioactive molecule a larger sample of peptide “hit” sequences is necessary.
Furthermore, compounds 4.8 and 4.9 need to be evaluated in solution phase in order to
determine their quantitative binding affinities in order to determine their true ability to
interact with GLP-1R.

4.3 Conclusions

In this chapter, an organometallic OBOC peptide library was synthesized
containing octapeptides with an N-terminal PADA-rhenium(I) tricarbonyl complex.
Random beads from the library were selected and MALDI tandem mass spectrometry
was used to determine the identity of the peptide sequences on the bead. A fifty percent
success rate was obtained in the sequencing of the unknown peptide sequences. These
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results have demonstrated that rhenium(I) tricarbonyl-containing peptide sequences can
be deconvoluted using MALDI tandem mass spectrometry.
The library was then screened against cells over-expressing the GLP-1R in order
to identify bioactive organometallic peptide sequences. Two such peptide sequences
were identified, although the use of a fluorescence microscope was resorted to as a
method to identify fluorescent beads due to failure to find proper sorting conditions for
red cells. This is the first reported example of an organometallic OBOC peptide library
screened against a biological target for bioactive molecules. Two such sequences are not
enough data to determine patterns and infer relationships between the structure of the
ligand and its correlation with the binding affinity. These sequences need to be further
evaluated in solution phase to determine their quantitative binding affinity.

4.4 Experimental
4.4.1 General Procedures

All chemicals and solvents were purchased from commercially available sources
and used without further purification. Coupling agents, resin and Fmoc amino acids were
purchased from Peptides International (Louisville, KY) or Aapptec (Louisville, KY).
Solvents and other chemicals were purchased from Fisher Scientific and Sigma Aldrich.
Automated peptide synthesis was done using an Advanced ChemTech Apex Multiple
Peptide Synthesizer. Bead sorting was accomplished using a Union Biometrica COPAS
BIOSORT instrument. Fluorescence was investigated using a fluorescence microscope.
MALDI mass spectrometry experiments were done utilizing an Applied Biosystems 4700
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PDS. This instrument is equipped with an Nd: YAG laser tuned to a wavelength of 355
nm, with a 200 Hz laser rate operating in reflectron mode and tandem time-of-flight ion
detectors in series. The mass spectrometer was calibrated with a mixture of angiotensin I
(m/z 1296.685), Glu-1-Fibrino-peptide B (m/z 1570.677) to a mass accuracy of ± 0.5 Da.

4.4.2 Single Bead Organometallic Peptide Synthesis

Re(CO)3-QATDKFTF-NH2 (3.2)
The peptide synthesis was carried out on tentagel S NH2 resin (0.1 mmol) and
using standard Fmoc peptide synthesis. Fmoc-ANP-OH (0.4 mmol, 4 eq.) was dissolved
in DMF (1mL) and combined with HCTU (0.4 mmol, 4 eq.) and DIPEA (0.8 mmol, 8
eq.). The mixture was agitated for three hours and the process repeated once. The
peptide was then deprotected using 20% piperidine in DMF (v/v) and the amino acids
were coupled sequentially. 2.7 (0.4 mmol, 4 eq.) was dissolved in DMF (2 mL) with
HCTU (0.4 mmol, 4 eq.) and DIPEA (0.8 mmol, 8 eq.) and mixed with peptide
containing the resin. The resin and solution were agitated overnight and subsequently
washed with DMF and DCM resulting in the desired organometallic peptide.

The

organometallic peptide was cleaved from resin by selecting a single bead under a
fluorescence microscope and irradiated with UV light for three hours in 50 µL of water.
The solution was then sequenced via MALDI TOF/TOF.
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4.4.3 OBOC Library Synthesis

OBOC peptide libraries were synthesizer utilizing the Advanced ChemTech
Multiple Peptide Synthesizer. The libraries were created with the seventeen natural
amino acids with the exclusion of methionine, cysteine and isoleucine. Tentagel S NH2
resin (1.30 g, 0.33 mmol) with a loading of 0.26 mmol/g. Fmoc-ANP-OH (1.42 g, 3.30
mmol, 10 eq.) was coupled to the resin using standard double coupling Fmoc peptide
synthesis procedures. The resin was then kept in the dark for the rest of the procedure.
The resin was divided into seventeen equal portions (0.07 g, 0.02 mmol) and placed in a
single well. The Fmoc was removed using 20% piperidine in DMF (v/v) (800 µL/well)
repeated twice and to each well a different amino acid (0.10 mmol, 5 eq.) was coupled
using HCTU (0.04 g, 0.10 mmol, 5 eq.) and DIPEA (0.035 mL, 0.20 mmol, 10 eq.) in
DMF (2.4 mL), rinsed and repeated. The resin was rinsed in DCM and recombined in a
beaker. The resin was mixed thoroughly and divided into seventeen equal portions and
placed back in the wells. The process of deprotection and coupling of amino acids was
repeated seven more times creating a library of octapeptides. The resin was removed
from the wells, the Fmoc was removed and coupled with compound 2.7, Re(CO)3-PADA
(0.51 g, 1.0 mmol, 3 eq.), HCTU (0.41 g, 1.0 mmol, 3 eq) and DIPEA (0.350 mL, 2.0
mmol, 6 eq.) in DMF overnight. This results in an organometallic Re(CO)3-PADA
octapeptide OBOC library. The purity of the library was verified by MALDI MS.
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4.4.4 Cell Growth

The CHO-GLP-1R/tdtomato cells were grown in F-12K media/10% FBS plus 200 µg/ml
G418 and 1 mg/mL hygromycin in order to maintain the stable expression of GLP-1R
and tdtomato, respectively. The CHO-EGFP cells were grown in F-12K media/10% FBS
plus 1 mg/mL G418 in order to maintain stable EGFP expression.

4.4.5 Library Incubation

The library was washed with dichloromethane, methanol and three times with
aqueous PBS (phosphate buffered saline). The cells were dissociated with 2 mM EDTA,
collected, spun down and then resuspended in HBSS (Hank's buffered saline solution) at
density of 2 x 106 cells/mL. 20 x 106 cells were plated in a 10 cm Petri dish and the
beads (approximately 1.5 million beads) were added to the dish. The dish was agitated at
70 rpm for 1 hour, in a humidified 37 oC incubator. Paraformaldehyde was added to the
dish to a final concentration of 4 % and incubated at room temperature for 10 minutes
and placed in a 40 mL falcon tube. The beads settled at the bottom and the cell-bead
pellet was washed twice with PBS.

4.4.6 Library Screening

The library, having previously been incubated with CHO cells, was screened
using a Union Biometrica COPAS biosorter. The library was suspended in PBS solution
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and mixed thoroughly. The biosorter measured the size and green fluorescence and
separated the beads into two populations, one with fluorescent cells and one without.
This was verified by investigation under the fluorescence microscope. The population
without the cells was washed with methanol and PBS.

The population was then

incubated again with CHO cells over-expressing the GLP-1R and expressing the red
fluorescent protein tdTomato. The incubation proceeded through an identical method
outlined above. An inverted fluorescent microscope was used to separate the beads
containing red fluorescent cells.

4.4.7 MALDI Tandem Mass Spectrometry

Beads were isolated via use of a fluorescent microscope and the beads were
placed in 50 µL of water and then irradiated with UV light for three hours. An aliquot of
the organometallic peptide solution (2 µL) and a CHCA solution (2 µL) were mixed for a
few minutes. CHCA solution is a mixture of 50:50 water/acetonitrile (v/v) with the
addition of 0.1% TFA at a concentration of 5 mg/mL. A portion of the mixture (0.7 µL)
was then spotted onto a MALDI plate in duplicate for analysis. The solvent in the
mixture was allowed to evaporate resulting in the co-crystallization of the matrix and
peptide. The samples were then analyzed via MALDI tandem mass spectrometry. The
precursor ion spectra show rhenium 185/187 isotopic distributions. The rhenium-185
peak was chosen for fragmentation via collision-induced dissociation with argon gas.
Tandem mass spectra were obtained and peaks assigned via manual de novo analysis.
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Chapter 5: Conclusions
Molecular imaging has become an important part of modern medicine due to its
ability to obtain information assisting in diagnosis in a non-invasive manner.1

The

development of new nuclear imaging technology relies on developments from a wide
variety of scientific and medical fields; the production and accessibility of radioisotopes,
knowledge of potential biological targets and the development of new imaging agents,
among many others, are all important in furthering the applicability and use of nuclear
medicine.
The research in this dissertation utilizes OBOC (one-bead, one-compound)
combinatorial peptide libraries to further the development of imaging agents by the
incorporation of organometallic coordination compounds into the library. Synthesis of
rhenium(I) tricarbonyl chelates as non-radioactive surrogates for technetium-99m, the
most widely used medical radioisotope, is discussed as well as the incorporation of the
chelates into peptide backbones.

The ability to sequence rhenium(I) tricarbonyl-

containing peptides through MALDI tandem mass spectrometry has been successful for
all chelates investigated. Furthermore, an organometallic OBOC peptide library was
applied to the discovery of new GLP-1R (glucagon-like peptide 1 receptor) candidate
imaging agents for diabetes and insulinomas.
Four rhenium(I) tricarbonyl chelates have been synthesized, PADA, BPA, NTA
and PHA, and were attached directly to the N-terminus of a peptide chain. These chelates
were chosen because they provide a good representation of the variety of chelates
associated with the rhenium(I) tricarbonyl metal centre. Re(CO)3-PADA, is known to be
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a stable chelate52 that forms neutral complexes.

Re(CO)3-BPA and Re(CO)3-NTA

provides positively and negatively charged coordination compounds, while Re(CO)3PHA is a novel chelation system holding a neutral charge. An investigation into the
ability to identify unknown organometallic amino acid sequences through the use of
MALDI tandem mass spectrometry has been accomplished. The results of this study into
organometallic peptide fragmentation patterns lead to the conclusion that a wide variety
of peptide chelation systems can be successfully incorporated on the N-terminus of the
peptide and these chains can be sequenced by MALDI TOF/TOF.

All rhenium(I)

tricarbonyl peptides were successfully sequenced by tandem mass spectrometry.
Re(CO)3-PADA and Re(CO)3-BPA peptides provide intense and easily identifiable
amino acid fragments. The fragmentation pattern of the Re(CO)3-NTA peptide does not
have complete fragmentation series, however was still successfully sequenced. The
Re(CO)3-PHA peptide is the first known example of a phenol based rhenium(I)
tricarbonyl chelate bound to an amino acid chain. The fragmentation pattern of the
Re(CO)3-PHA peptide compound allowed for the successful identification of the peptide
sequence, as well as the unique observation of the fragmentation of the PHA chelate
resulting in the neutral loss of orthoquinone methides.

The results of the MALDI

TOF/TOF sequencing experiments indicate that a wide variety of rhenium(I) tricarbonyl
chelates can be identified in this manner.
An N-terminal Re(CO)3-PADA OBOC peptide library was synthesized containing
approximately 1.5 million unique peptide sequences utilizing all natural amino acids with
the exception of cystiene, isoleucine and methionine. The library was screened against
fluorescent CHO (Chinese hamster ovarian) cells over-expressing the GLP-1 receptor in
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order to identify imaging agent candidates for use in diabetes or insulinoma diagnosis and
monitoring.

Two

organometallic

peptide

sequences,

Re(CO)3-PADA-

RVTH(K/Q)(K/Q)(K/Q)E-NH2 and Re(CO)3-PADA-SWGxxLFS-NH2, were isolated
from the library and identified by tandem mass spectrometry. Cells were attached to the
beads that contained these two organometallic peptides.

Because only two “hit”

sequences were isolated, inferences into the structure-activity relationships cannot be
conclusively made.
Recent developments of OBOC peptide libraries have focused on the
incorporation of unnatural and non-peptide-like structures into combinatorial libraries.
OBOC libraries are robust to a wide variety of chemistry, which is one of their main
advantages in comparison to other combinatorial libraries. Additions of unnatural amino
acids97 and quaternary ammonium salts98 have been recently reported. Moreover, OBOC
peptoid (N-substituted oligo-glycines) libraries96 have been developed. Additionally, the
identification of peptoid structures through tandem mass spectrometry has also been
shown.

Non-natural peptide-like structures are generally more stable to in vivo

conditions, which is an important property of pharmaceuticals and imaging agents. The
research in this dissertation utilizes the same benefits of OBOC libraries to further utilize
non-peptide structures to improve the development of nuclear imaging agents.
Rhenium(I) tricarbonyl-containing OBOC peptide libraries have unnatural radionuclide
surrogates in order to account for their influence on receptor binding affinity. This
advance in molecular imaging has the ability to alter the way in which peptide-based
imaging agents are developed.

For the discovery of novel imaging agents, the

organometallic OBOC peptide methodology outlined in this dissertation is superior to the
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traditional OBOC approach. Furthermore, organometallic OBOC peptide libraries could
be used to investigate the influence of a large number of different imaging entity
surrogates on known bioactive peptides.
In conclusion, novel organometallic OBOC peptide libraries have been
synthesized through standard peptide chemistry, MALDI tandem mass spectrometry has
been identified as a useful technique to deconvolute organometallic peptide sequences
and a Re(CO)3-PADA peptide library has been used to identify potential imaging agents
for the GLP-1R.

This technique has the potential to be applied to any number of

radionuclide surrogates. However, fragmentation patterns and chelate stability under
fragmentation conditions would need to be investigated. Organometallic OBOC peptide
libraries provide a new methodology to expedite and economize the process of peptidebased imaging agent discovery.
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APPENDIX I – CHAPTER 2
1

H NMR and 13C NMR spectra of 2.3
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H NMR spectrum of 2.4
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H NMR spectrum of 2.5
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H NMR and 13C NMR spectra of 2.6
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H NMR and 13C NMR spectra of 2.7
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H NMR and 13C NMR spectra of 2.8
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H NMR and 13C NMR spectra of 2.9
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H NMR and 13C NMR spectra of 2.10
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H NMR and 13C NMR spectra of 2.11
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H NMR and 13C NMR spectra of 2.12a
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1

H NMR spectrum of 2.12b
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H NMR spectrum of 2.12c
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H NMR and 13C NMR spectra of 2.13
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H NMR and 13C NMR spectra of 2.14
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APPENDIX II – Chapter 3
HPLC trace and ES+ mass spectrum of 3.2
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HPLC trace and ES+ mass spectrum of 3.3
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HPLC trace and ES+ mass spectrum of 3.4
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HPLC trace and ES+ mass spectrum of 3.6
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APENDIX III – Chapter 4
For all organometallic peptide product ion spectra, the rhenium-185 was selected for
fragmentation
The MS/MS spectrum of compound [PADA-Re(CO)3]-VLYGVRPV-NH2 (4.1) and b
series peak assignments
[M+H]+ calc: 1335.51, obs: 1335.49 (rhenium-187 peak)
Series

Label

b0
b1
b2
b3
b series b4
b5
b6
b7
b8

Fragment

NOT OBSERVED
RE-PADA-V
RE-PADA-VL
RE-PADA-VLY
RE-PADA-VLYG
RE-PADA-VLYGV
RE-PADAVLYGVR
RE-PADAVLYGVRP
NOT OBSERVED

Peak
(m/z)

Difference
between
peaks (m/z)

Amino Acid
Assignment

475.0
574.1
687.2
850.2
907.3
1006.3

99.1
113.1
163.0
57.1
99.0

Valine
Leucine
Tyrosine
Glycine
Valine

1120.3

114.0

Asparginine

1217.4
1316.5

97.1
99.0

Proline
Valine
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The MS/MS spectrum of compound [PADA-Re(CO)3]-ALHEVGSW-NH2 (4.2) and b
series peak assignments
[M+H]+ calc: 1373.46, obs: 1373.43 (rhenium-187 peak)
Series

b
series

Label

b0
b1
b2
b3
b4
b5
b6
b7
b8

Fragment

NOT OBSERVED
RE-PADA-A
RE-PADA-AL
RE-PADA-ALH
RE-PADA-ALHE
RE-PADA-ALHEV
RE-PADA-ALHEVG
RE-PADAALHEVGS
NOT OBSERVED

Peak
(m/z)

Difference
between
peaks (m/z)

Amino Acid
Assignment

475.0
546.1
659.1
796.2
925.3
1024.3
1081.3

71.1
113.0
137.1
129.1
99.0
57.0

Alanine
Leucine
Histidine
Glutamic Acid
Valine
Glycine

1168.3
1354.4

87.0
186.1

Serine
Tryptophan
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The MS/MS spectrum of compound [PADA-Re(CO)3]-HNES(K/Q)EGT-NH2 (4.3) and b
series peak assignments
[M+H]+ calc: 1376.38, obs: 1376.43 (rhenium-187 peak)
Series

b
series

Labe
l
b0
b1
b2
b3
b4
b5
b6
b7
b8

Fragment

NOT OBSERVED
RE-PADA-H
RE-PADA-HN
RE-PADA-HNE
RE-PADA-HNES
RE-PADA-HNES(K/Q)
RE-PADAHNES(K/Q)E
RE-PADAHNES(K/Q)EG
NOT OBSERVED

Peak
(m/z)

Difference
between
peaks (m/z)

Amino Acid
Assignment

475.0
612.1
726.1
855.2
942.2
1070.3

137.01
114
129.1
87
128.1

Histidine
Asparginine
Glutamic Acid
Serine
Lysine/Glutamine

1199.3

129

Glutamic Acid

1256.3
1357.4

57
101.1

Glycine
Threonine
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The MS/MS spectrum of compound [PADA-Re(CO)3]-FEGGEESY-NH2 (4.4) and b
series peak assignments
[M+H]+ calc: 1392.40, obs: 1392.37 (rhenium-187 peak)
Series

b
series

Labe
l
b0
b1
b2
b3
b4
b5
b6
b7
b8

Fragment

NOT OBSERVED
RE-PADA-F
RE-PADA-FE
RE-PADA-FEG
RE-PADA-FEGG
RE-PADA-FEGGE
RE-PADA-FEGGEE
RE-PADA-FEGGEES
NOT OBSERVED

Peak
(m/z)
475.0
622.1
751.1
808.2
865.2
994.2
1123.2
1210.3
1373.3

Difference
between
peaks (m/z)
147.1
129
57.1
57
129
129
87.1
163

Amino Acid
Assignment

Phenylalanine
Glutamic Acid
Glycine
Glycine
Glutamic Acid
Glutamic Acid
Serine
Tyrosine

150

The MS/MS spectrum of compound [PADA-Re(CO)3]-YARES(K/Q)AD-NH2 (4.5) and
b series peak assignments
[M+H]+ calc: 1414.47, obs: 1414.45 (rhenium-187 peak)
Series

b
series

Labe
l
b0
b1
b2
b3
b4
b5
b6
b7
b8

Fragment

NOT OBSERVED
RE-PADA-Y
RE-PADA-YA
RE-PADA-YAR
RE-PADA-YARE
RE-PADA-YARES
RE-PADAYARES(K/Q)
RE-PADAYARES(K/Q)A
NOT OBSERVED

Peak
(m/z)

Difference
between
peaks (m/z)

Amino Acid
Assignment

475.0
638.1
709.2
865.3
994.3
1081.2

163.1
71.1
156.1
129.1
86.9

Tyrosine
Alanine
Arginine
Glutamic Acid
Serine

1209.4

128.1

Lysine/Glutamine

1280.4
1395.4

71.1
115.0

Alanine
Aspartic Acid
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The MS/MS spectrum of compound [PADA-Re(CO)3]-DHHLRAYV-NH2 (4.6) and b
series peak assignments
[M+H]+ calc: 1443.48, obs: 1443.46 (rhenium-187 peak)
Series

b
series

Labe
l
b0
b1
b2
b3
b4
b5
b6
b7
b8

Fragment

NOT OBSERVED
RE-PADA-D
RE-PADA-DH
RE-PADA-DHH
RE-PADA-DHHL
RE-PADA-DHHLN
RE-PADA-DHHLNA
RE-PADA-DHHLNAY
NOT OBSERVED

Peak
(m/z)
475.0
590.1
727.1
864.6
977.3
1091.3
1162.3
1325.5
1424.4

Difference
between
peaks (m/z)
115.1
137.1
137.5
112.7
114.0
71.0
163.1
99.0

Amino Acid
Assignment

Aspartic Acid
Histidine
Histidine
Leucine
Asparginine
Alanine
Tyrosine
Valine
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The MS/MS spectrum of compound [PADA-Re(CO)3]-TEHNP(K/Q)HE-NH2 (4.7) and b
series peak assignments
[M+H]+ calc: 1466.44, obs: 1446.48 (rhenium-187 peak)
Series

b
series

Labe
l
b0
b1
b2
b3
b4
b5
b6
b7
b8

Fragment

NOT OBSERVED
RE-PADA-T
RE-PADA-TE
RE-PADA-TEH
RE-PADA-TEHN
RE-PADA-TEHNP
RE-PADATEHNP(K/Q)
RE-PADATEHNP(K/Q)H
NOT OBSERVED

Peak
(m/z)

Difference
between
peaks (m/z)

Amino Acid
Assignment

475.0
576.1
705.2
843.2
956.2
1053.3

101.1
129.1
137
114
97.1

Threonine
Glutamic Acid
Histidine
Asparginine
Proline

1181.4

128.1

Lysine/Glutamine

1318.4
1447.5

137
129.1

Histidine
Glutamic Acid
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